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Role of Calpains in Axonal Injury and Degeneration
Abstract
Axonal injury and degeneration, whether primary or secondary, contribute to the morbidity and mortality
seen in many acquired and inherited central nervous system (CNS) and peripheral nervous system (PNS)
disorders, such as traumatic brain injury (TBI), spinal cord injury, cerebral ischemia, neurodegenerative
diseases, and demyelinating and hereditary neuropathies. The calpain family of proteases has been
causally linked to many of these acute and chronic disorders. In particular, previous studies have
suggested that pathologic calpain activity may be responsible for axonal dysfunction and degeneration.
Even though the immediate cause of increased intra-axonal calpain activity varies, the downstream
effects of calpains may be similar. To address the role of calpains in axonal injury, I have relied on two
animal models: nerve transection and optic nerve stretch. First, I demonstrated that overexpression of the
endogenous calpain inhibitor, calpastatin, in transgenic mice provided biochemical and morphological
protection to transected PNS axons, and biochemical protection to CNS axons. I then studied the role of
calpains in synaptic dysfunction in transected PNS axons. There was no detectable protection of synaptic
function with calpastatin overexpression. Next, I developed and characterized a new in vivo model of
optic nerve stretch that isolates mechanical strain primarily to axons of retinal ganglion cells in the rat.
This model of optic nerve stretch recapitulates the signature pathology seen in axons after human TBI,
which is transport disruption. Within my study of optic nerve stretch, I used both the pharmacologic
calpain inhibitor MDL-28170 and adeno-associated viral vector-mediated overexpression of calpastatin to
examine the role of calpains in impairment of retrograde transport after mechanical stretch of axons.
Calpastatin overexpression, but not short-duration MDL-28170, protected retrograde axonal transport.
Taken together, my dissertation work extends our understanding of the pathologic role of calpains in
axonal injury and degeneration.
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ABSTRACT
ROLE OF CALPAINS IN AXONAL INJURY AND DEGENERATION
Marek Ma
Robert W. Neumar

Axonal injury and degeneration, whether primary or secondary, contribute to the
morbidity and mortality seen in many acquired and inherited central nervous system
(CNS) and peripheral nervous system (PNS) disorders, such as traumatic brain injury
(TBI), spinal cord injury, cerebral ischemia, neurodegenerative diseases, and
demyelinating and hereditary neuropathies. The calpain family of proteases has been
causally linked to many of these acute and chronic disorders. In particular, previous
studies have suggested that pathologic calpain activity may be responsible for axonal
dysfunction and degeneration. Even though the immediate cause of increased intraaxonal calpain activity varies, the downstream effects of calpains may be similar. To
address the role of calpains in axonal injury, I have relied on two animal models: nerve
transection and optic nerve stretch. First, I demonstrated that overexpression of the
endogenous calpain inhibitor, calpastatin, in transgenic mice provided biochemical and
morphological protection to transected PNS axons, and biochemical protection to CNS
axons. I then studied the role of calpains in synaptic dysfunction in transected PNS
axons. There was no detectable protection of synaptic function with calpastatin
overexpression. Next, I developed and characterized a new in vivo model of optic nerve
stretch that isolates mechanical strain primarily to axons of retinal ganglion cells in the
rat. This model of optic nerve stretch recapitulates the signature pathology seen in axons
after human TBI, which is transport disruption. Within my study of optic nerve stretch, I
used both the pharmacologic calpain inhibitor MDL-28170 and adeno-associated viral
v

vector-mediated overexpression of calpastatin to examine the role of calpains in
impairment of retrograde transport after mechanical stretch of axons. Calpastatin
overexpression, but not short-duration MDL-28170, protected retrograde axonal
transport. Taken together, my dissertation work extends our understanding of the
pathologic role of calpains in axonal injury and degeneration.
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CHAPTER 1:
Introduction: mechanistic roles of calpains in
axonal injury and degeneration

1

Abstract
Axonal injury and degeneration, whether primary or secondary, contribute to the
morbidity and mortality seen in many acquired and inherited central nervous system
(CNS) and peripheral nervous system (PNS) disorders, such as traumatic brain injury,
spinal cord injury, cerebral ischemia, neurodegenerative diseases and demyelinating
and hereditary neuropathies. The calpain family of proteases has been linked to the
pathology seen in axons. Even though the direct mechanism by which mechanical strain,
ischemia or demyelination, may trigger calpain activity may be different, the downstream
intra-axonal effects of unregulated calpain activity may be similar in these seemingly
disparate diseases. In this chapter, I briefly review key elements of axonal structure and
provide a focused overview of the calpain family. Finally, I discuss the mechanisms by
which calpains may disrupt the axonal cytoskeleton and transport, specialized electrical
domains (axon initial segment and nodes), and axon terminals.
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I. Introduction
A growing body of work over the past 20 years suggests that the calpain family of
Ca2+ dependent cysteine proteases is partly responsible for axonal cytoskeletal
degeneration and axonal dysfunction. In addition to a unique cytoskeleton, axons have
specialized transport processes as well as electrical and signaling domains, which are
disrupted in various experimental injury models. Strategies to injure axons, such as
transection, stretch, and oxygen deprivation, are known to activate intra-axonal calpains.
In this chapter, I describe the findings from these disparate lines of investigations to
present a unified understanding of the pathologic roles that calpains plays within the
axon.

II. Axonal injury and degeneration underlie common neurologic diseases
A. Traumatic brain injury
Worldwide, traumatic brain injury (TBI) leading to death or hospitalization is
estimated to afflict over 10 million people annually, and is predicted to surpass many
diseases as the major cause of death and disability by the year 2020 (Hyder et al.,
2007). There are no approved therapies that specifically targets the molecular cascades
acutely triggered by TBI. A significant contribution to the morbidity and mortality of TBI is
from axonal injury (Blumbergs et al., 1995; Povlishock and Becker, 1985; Smith and
Meaney, 2000). It is estimated that traumatic axonal injury (TAI) accounts for at least
35% of the morbidity and mortality in blunt TBI patients without space-occupying lesions
(Büki et al., 2000). In blunt TBI, rotational and shearing forces disproportionately affect
the long white matter tracts. Axons may stretch on the order of 15 to 30% of their original
length in susceptible brain regions (Saatman et al., 2003). Except in the most severe
cases, where axons tear at the moment of trauma, injured axons initially show no overt
3

disconnection but subsequently lose continuity and degenerate (Jafari et al., 1997;
Maxwell and Graham, 1997; Povlishock and Katz, 2005; Saatman et al., 2003).

B. Spinal cord injury
In the United States, there are over 250,000 people living with spinal cord injury
(SCI; Ray et al., 2011). Like TBI, the victims of SCI are mostly young adults who would
otherwise be in productive phases of their lives. The only approved therapy for SCI is
methylprednisolone, but its efficacy is highly controversial (Ray et al., 2011). The
neurological deficits are predominantly caused by loss of white matter, particularly the
long tracts through which ascending and descending communications between the brain
and PNS occur (Medana and Esiri, 2003). Immediately after fatal SCI in humans, a
proportion of axons was determined to be injured but not transected (Medana and Esiri,
2003). These injured axons had irregular varicosities, spheroids and ß-APP
immunoreactivity. ß-amyloid precursor protein (ß-APP) accumulates at sites of
presumably disrupted axonal transport (Ma et al., 2012). The pathophysiology of SCI is
extremely complex, and isolating the axonal contribution is challenging in experimental
models.

C. Cerebral ischemia
Cerebral ischemia can be global or focal. Worldwide, the incidence and burden of
cardiac arrest and stroke are staggering (Berdowski et al., 2010; Bramlett and Dietrich,
2004; Gustavsson et al., 2011; Kinlay, 2011). In humans, about 50% of the brain volume
is white matter, which is almost always involved to some degree in stroke (Goldberg and
Ransom, 2003). Axons often extend for long distances from their somata, and may
suffer ischemia that do not involve their parent neurons (Medana and Esiri, 2003). Axons
4

are sensitive to ischemia and hypoxia (Pantoni et al., 1996; Underhill and Goldberg,
2007), and disruption of central conducting pathways may cause significant morbidity in
patients.

D. Traumatic injury to peripheral nerves
Traumatic injury to peripheral nerves results in considerable worldwide disability
(Robinson, 2000). There are three types of traumatic nerve injury: neuropraxia,
axonotmesis and neurotmesis. Neuropraxia is comparatively mild, with motor and
sensory loss owing to conduction block but no evidence of axonal degeneration, and has
an excellent prognosis. Brief ischemia or focal demyelination is the suspected cause.
Axonotmesis is commonly caused by nerve crush or stretch, where the axon and myelin
sheath are interrupted but the surrounding basal lamina and collagen remain in
continuity. Nerve crush or stretch may result in a population of axons that are injured but
not transected, and therefore potentially salvageable. Nerve transection results in
neurotmesis, where there is interruption of the continuity of the axon and surrounding
connective tissue components and basal lamina, and the prognosis is typically poor.

E. Other diseases
In addition to trauma and ischemia, axonal dysfunction and degeneration are
important contributors to the morbidity and mortality of many human diseases, such as
multiple sclerosis and other demyelinating diseases, infections (malaria and HIV),
neurodegenerative diseases, and peripheral and hereditary neuropathies (Coleman,
2005; Glass, 2004; Medana and Esiri, 2003; Shaw, 2005; Shy et al., 2002). Thus,
understanding axon physiology and pathology is critically important to developing
therapeutic strategies for a broad spectrum of neurological disorders.
5

III. Axonal Structure and Function

For the purposes of this chapter, axon regions will be grouped into the following:
axon initial segment (AIS) and nodal domains, axon proper, and synaptic terminals.
Action potential is initiated at the AIS, propagated down the axon proper, where it signals
the release of neurotransmitters at the synapse (see review by Debanne et al., 2011).
There are two broad types of axons, myelinated and unmyelinated. Myelination is
accomplished by oligodendrocytes in the CNS and by Schwann cells in the PNS. In
myelinated axons, action potentials are propagated via saltatory conduction, which
allows for increased speed of transmission. Ion channels cluster at the AIS and nodes as
well as in the terminals via ankyrins and spectrins. These specialized domains will be
described in more detail later. In contrast, unmyelinated axons are generally smaller in
diameter with more homogenous distribution of ion channels and therefore slower
conduction.
The axon cytoskeleton is principally composed of neurofilaments (NF) and
microtubules. The third type of protein filament, actin, is concentrated in dendritic spines,
growth cones, and presynaptic terminals. Disruption and disintegration of the
cytoskeleton are pathologic “signatures” of axonal injury and degeneration.
Neurofilaments are the most abundant cytoskeletal protein in large myelinated axons
and are longitudinally oriented and regularly spaced (see review by Perrot et al., 2008).
They are ~10 nm in diameter and consist of heteropolymers of subunits with molecular
weights of about 68, 160, and 200 kDa, known respectively as light (NFL), medium
(NFM), and heavy (NFH) subunits. Each subunit has a central 40 kDA core domain,
which is used to form coiled-coil structures with other neurofilaments, allowing for self6

assembly. The two larger isoforms are heavily phosphorylated, mainly in the carboxyterminal domain (commonly called the sidearm). Phosphorylation of the sidearms may
influence inter-neurofilament distance and axonal caliber, an important determinant of
conduction velocity of action potentials (Perrot et al., 2008). Phosphorylation is
topographically regulated as heavily phosphorylated neurofilaments are preferentially
located in axons, while less phosphorylated neurofilament are in the somatodendritic
regions.
Microtubules are critically important for anterograde and retrograde transport.
Disruption of axonal transport is commonly seen after TBI and has been attributed to
depolymerization or loss of microtubules (Maxwell, 1996; Maxwell and Graham, 1997;
McCracken et al., 1999; Saatman et al., 2003). Microtubules are hollow cylindrical
structures with diameters of ~25 nm built from 13 parallel protofilaments, each
composed of alternating α- and β-tubulin molecules. In the axon, they are oriented with
their plus ends outward or away from the soma. Their assembly, stability, and
disassembly are regulated by microtubule-associated proteins (MAPs; Amos and
Schlieper, 2005). Tau is highly enriched in axons, while MAP1 has a widespread
neuronal distribution (Bloom et al., 1984; Maccioni and Cambiazo, 1995; Noble et al.,
1989). In contrast, MAP2 is not found in axons in the mature nervous system (Maccioni
and Cambiazo, 1995).

IV. The Calpain/Calpastatin System
A. Overview
Calpains are a family of Ca2+-dependent non-lysosomal proteases involved in
cytoskeletal remodeling, signal transduction, cell differentiation, embryonic development,
vesicular trafficking, apoptosis, and necrosis (Zatz and Starling, 2005). Since the
7

discovery of µ-calpain in 1964 (Guroff, 1964), it is now recognized that the human
genome contains 15 genes that encode calpain-like proteases. Several calpain catalytic
subunit isoforms (1, 2 3, 5, and 10), two small regulatory subunits, and the endogenous
inhibitor calpastatin, have been identified in brain.
The most well-studied calpains are the ubiquitous µ- and m-calpain. These are
heterodimers that consist of 80 kDa catalytic subunits sharing 50% sequence homology
(calpain 1 and calpain 2, respectively) and a common 30 kDa regulatory subunit, known
as (CSS)1 or calpain 4. Consistent with the scientific nomenclature, µ- and m-calpain
refer to the heterodimers, while calpain 1 and 2 refer to the individual catalytic subunits.
The major functional difference between µ- and m-calpain is the in vitro Ca2+
concentration required for half-maximal activity (the EC50), 3-50 µM and 400-800 µM,
respectively (Goll et al., 2003). Autoproteolysis of calpain reduces the Ca2+ concentration
required for its activity.
Much less is known about the other three catalytic isoforms found in brain.
Calpain 3, which is a monomeric isoform once thought to be muscle-specific, has a
domain organization similar to that of calpains 1 and 2. Even though it has been
detected in neuron-like PC12 cells (Marcilhac et al., 2006), calpain 3 is localized to
astrocytes, but not neurons, in the rodent and primate brain (König et al., 2003). Calpain
5 mRNA is present in rat and human brain (Waghray et al., 2004), but the protein has
not been detected in brain. Calpain 10 protein has been found in rat brain homogenates
(Ma et al., 2001), and has been localized to mitochondria, where it plays a pathologic
role in mitochondrial dysfunction via cleavage of Complex 1 subunits and activation of
mitochondrial permeability transition (Arrington et al., 2006; Kar et al., 2010). µ- and mcalpains have also been identified in mitochondria. Even though mitochondrial
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dysfunction may contribute to axonal pathology, the role of calpains in mitochondrial
dysfunction is beyond the scope of this review.
Calpastatin is an endogenous inhibitor of both µ- and m-calpain, and is not
known to inhibit proteases of any other family (Goll et al., 2003). Whether or not
calpastatin inhibits the other calpain isoforms has not been definitively established.
There is a single calpastatin gene located on chromosome 5 in humans, but through
alternative splicing, isoforms ranging in molecular mass from 17.5 to 84 kDa have been
identified.
Currently, there are no pharmacologic inhibitors completely specific for calpains
or individual calpain isoforms (Goll et al., 2003). The cell-permeable MDL-28170 is one
of the most well studied calpain inhibitor and ameliorates TAI in global brain injury
models (Ai et al., 2007; Büki et al., 2003). It does inhibit cathepsin B, although it is
somewhat more selective for calpains (Ki = 25 and 10 nmol/L for cathepsin B and
calpain, respectively) (Markgraf et al., 1998). Another commonly used calpain inhibitor,
ALLN has similar potency for cathepsins B and D and µ- or m-calpains, and has some
activity against the proteasome (product data sheet; BioVision Research Products,
Mountain View, CA).
Calpains cleave their substrates in a limited manner, often modifying, rather than
terminating, their function (Sorimachi et al., 2010; Tompa et al., 2004). There is no
definitive method to predict which substrates are proteolyzed by calpains or to determine
the calpain cleavage site (Ray, 2006). Even though they have nearly identical
substrates, µ- and m-calpain have different cellular localization and serve unique
functions (Honda et al., 2004). Constitutive knockout of calpain 2 or the common small
regulatory subunit, which is required for stability and activity of both µ- and m-calpain, is
embryonically lethal (Arthur et al., 2000; Dutt et al., 2006), while calpain 1 knockout mice
9

are viable and fertile (Azam et al., 2001). Depending on experimental model, either µ- or
m-calpain may contribute to neuronal death. m-calpain promotes death of primary
hippocampal neurons following NMDA excitoxicity, whereas µ-calpain contributes to
hippocampal neuronal death after global brain ischemia (Bevers et al., 2009, 2010).

B. Localization of µ- and m-calpains in axons
All vertebrate cells examined so far have been found to express µ- and mcalpains (Goll et al., 2003). However, reports describing the subcellular localization of
calpains 1 and 2 are inconsistent. This is likely due to the relatively poor and variable
selectivity of antibodies for the two isoforms when used for immunohistochemistry.
Calpain 1 immunoreactivity was detected in myelinated and unmyelinated axons in brain
with rare staining of presynaptic terminals (Perlmutter et al., 1990; Siman et al., 1985). In
contrast, Hamakubo and colleagues (1986) localized calpain 2, but not calpain 1,
immunoreactivity to CNS myelinated axons. Calpain 2 immunohistochemistry in the PNS
resulted in staining of rat sciatic nerve axons (Mata et al., 1991). Even though the axonal
localization of calpains 1 and 2 has not been definitively established, calpain activity has
been identified throughout the axon and presynaptic compartment (O'Hanlon et al.,
2003; Saatman et al., 2003).

C. Recognition of calpain activity
In vivo calpain activity can be demonstrated by two methods: measuring
autoproteolysis and tracking substrate degradation. Autoproteolysis of µ-calpain occurs
in two stages. For human µ-calpain (80 kDa), 14 amino acids are first removed to
produce a 78-kDA intermediate product, followed by removal of an additional 12 amino
acids to produce the 76 kDa fragment (Goll et al., 2003). These forms can be resolved
10

by SDS-PAGE (Hayashi et al., 1991). Autoproteolysis of the 80-kDa subunit of human
m-calpain reduces the mass to 78 kDa, but this is difficult to resolve by SDS-PAGE and
therefore is an unreliable measure of m-calpain activation (Goll et al., 2003). The
cleavage sites are similar but not identical to calpains from other species.
Autoproteolysis is not required for calpain activity (Goll et al., 2003).
Substrate proteolysis as a measure of calpain activity can be detected by loss of
intact proteins or accumulation of lower molecular weight fragments. The most
commonly used substrate is the 280 kDA αII-spectrin, and its measurement by
immunoblotting or immunohistochemistry is a sensitive and specific way to assay for in
vivo calpain activity (Roberts-Lewis et al., 1994). Calpain activity rapidly generates 145and 150-kDA fragments, which lack the ability to self-associate and cross-link actin in
vitro (Harris and Morrow, 1990). There is an antibody (Ab38) that specifically recognizes
the C-terminus of the 150-kDA amino-terminal αII-spectrin fragment (Roberts-Lewis et
al., 1994).

V. Pathologic role of calpains in axons
I have decided to focus on calpain substrates that are either preferentially
localized to distinct axonal domains or that are important to unique axonal functions and
have been demonstrated to be proteolyzed under pathologic conditions. Calpain
substrates in the endoplasmic reticulum and mitochondria are reviewed elsewhere (see
Bevers and Neumar, 2008; Kar et al., 2010), and are beyond the scope of this chapter.
In addition, calpain substrates like the plasma membrane Ca2+ ATPase (PMCA) or Nmethyl-D-aspartic acid (NMDA) receptors, which are not preferentially localized to the
axonal or presynaptic compartments, are not discussed here.

11

A. Degeneration of the axon cytoskeleton in Wallerian degeneration
A.1. Overview of Wallerian degeneration
In 1849, Augustus Waller observed that nerve transection results in progressive
degeneration of the distal portion of the nerve (Waller, 1850). The initial pathology seen
in this process, now named Wallerian degeneration, is axonal degeneration and the final
step in the process is myelin clearance (see review by Vargas and Barres, 2007).
Experimental interruption of axons in vivo is typically done by nerve transection or crush.
Nerve transection results in neurotmesis, while nerve crush theoretically produces
axonotmesis. The course of degenerative events is identical between nerve transection
and crush (Chaudhry et al., 1992).
It was once believed that when axons are separated from their somata, the
cessation of anterogradely-delivered trophic factors were responsible for their passive
degeneration (Vargas and Barres, 2007). However, with the discovery of the Wallerian
degeneration slow mouse (Wlds), axonal degeneration is now established as an active
process. The Wlds mutation is an autosomal dominant, spontaneously occurring
mutation located on mouse chromosome 4. The Wlds gene mutation is an 85-kb tandem
triplication containing the full coding region of nicotinamide mononucleotide adenyl
transferase 1 (Nmat-1), the coding region for the N-terminal 70 amino acids of the
ubiquitination factor E4B (Ube4b), and a unique 18 amino acid linker. The precise
mechanism by which Wlds mediates axonal protection has not been clearly established,
but the bulk of the evidence favors a mitochondrial role of Nmnat-1 in preserving axons
(Coleman and Freeman, 2010).
After an axon is transected, there is a latency period before axonal degeneration
is evident. The latency period is typically longer in CNS than in PNS axons but not
always (George and Griffin, 1994). Transected axons undergo granular disintegration of
12

the cytoplasm (GDC), in which the organelles and cytoskeletal components disintegrate
(Vargas and Barres, 2007). GDC occurs in some CNS axons and all PNS axons. A
subpopulation of transected CNS axons undergoes “dark” degeneration, where the
axons become filled with electron-dense material that obscures visualization of
cytoskeletal structure (Marques et al., 2003; Narciso et al., 2001). Axons undergoing
“dark” degeneration are frequently of medium and small caliber, as opposed to larger
axons that undergo GDC. The functional significance of “dark” degeneration is unknown.
Transection-induced axonal degeneration in the mammalian CNS and PNS may
differ by onset and morphology, but ultimately all axon segments distal to the transection
site degenerate. Currently, the process is irreversible, and delaying this process may not
be clinically relevant. However, Wallerian degeneration has attracted much scientific
interest as the underlying molecular mechanisms may be common to many disorders.
Understanding Wallerian degeneration may reveal better clinical targets for a wide
spectrum of human diseases.

A.2. Cytoskeletal components are calpain substrates
Early investigators implicated calpains as causative agents of GDC (Fig. 1;
(Kamakura et al., 1985; Schlaepfer et al., 1984). All three neurofilament isoforms that
are degraded during GDC are calpain substrates (James et al., 1998; Kamakura et al.,
1983, 1985; Malik et al., 1987; Schlaepfer et al., 1984, 1985). Of the different
neurofilament isoforms, NFM appears to be most susceptible to proteolysis (Kamakura
et al., 1985). The calpain cleavage sites for the neurofilament isoforms have not been
established in mammals, except for two sites (after lys 467 and lys 516) identified in
bovine NFM (Shaw et al., 2004).
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In addition to neurofilaments, microtubules may be degraded during GDC (Donat
and Wisniewski, 1973; Schlaepfer, 1974). However, Zhai and colleagues (2003) have
suggested that the early loss of microtubules may not be due to degradation, but to
depolymerization, at least in vitro. Some but not all studies support that tubulin is a
calpain substrate (Billger et al., 1988; Malik et al., 1987; Sandoval and Weber, 1978). In
vitro calpain proteolysis of tubulin results in a ~50 kDA fragment that is quite similar in
size to intact tubulin (Billger et al., 1988). Calpains retard the assembly and promote the
disassembly of purified microtubules. Purified tubulin subjected to in vitro proteolysis by
calpain forms large aggregates without any obvious structure (Billger et al., 1988).
Microtubule depolymerization may also be due to proteolysis of microtubule associated
proteins (MAPs), which are critical for microtubule stability (Gordon-Weeks and Fischer,
2000; Johnson et al., 1989; Maccioni and Cambiazo, 1995; Sandoval and Weber, 1978;
Weingarten et al., 1975). MAP1 and tau are calpain substrates, and their proteolysis
generates multiple fragments (Fischer et al., 1991; Johnson et al., 1989; Sato et al.,
1986; Yang and Ksiezak-Reding, 1995). When a purified mixture of microtubules and
MAPs is incubated with calpain, MAP1 is degraded and no longer binds to microtubules
(Billger et al., 1988). Adding further complexity, microtubule depolymerization may result
directly from elevated Ca2+ or by Ca2+ activation of calmodulin (Gaskin et al., 1975; Job
et al., 1981; Keith et al., 1983; O'Brien et al., 1997). In the injured axon, it is difficult to
tease apart the role of calpains from the other effects of elevated Ca2+. The mechanism
of microtubule loss in GDC may be multifactorial.

A.3. Calpains and GDC in Wallerian degeneration
Direct evidence for the role of calpains in axonal degeneration initially came from
in vitro studies. Reducing extracellular Ca2+ or application of various pharmacologic
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calpain inhibitors decrease degeneration of transected neurites in dorsal root ganglia
(DRG) cultures (George et al., 1995; Wang et al., 2000). The calpain inhibitor ALLN
preserves neurofilament immunolabeling of transected neurites but not the axolemma as
assessed by differential interference contrast microscopy or immunostaining for the cellsurface antigen Thy-1.1 (Finn et al., 2000). In rat sympathetic superior ganglia (SCG)
explants, ALLN prevents neurofilament degradation after neurite transection, but is
unable to prevent microtubule fragmentation (Zhai et al., 2003). In contrast, EGTA and
pharmacologic inhibitors to the ubiquitin-proteasome system (UPS) prevent both
neurofilament degradation and microtubule fragmentation. One study did not find
statistically significant protection of axotomized neurites of mouse cortical neurons with
ALLN, but the wide variability may have obscured any drug effects (Kilinc et al., 2010).
Care must be exercised when extrapolating these experimental findings to axons in vivo,
as cultures consist of developmentally young neurons in a “simplified” extracellular
environment. Pharmacologic calpain inhibitors are also known to inhibit proteases
outside of the calpain family. Nonetheless, calpains may be important to some aspects
of neurite degeneration.
Two in vivo studies examining the role of calpains in axonal degeneration provide
discordant results. Glass and colleagues (2002) studied sciatic nerve transection in
C57Bl/6J mice. One hour after transection, there is increased Ab38, which specifically
detects calpain-cleaved spectrin, signal in sciatic nerve homogenates. Ab38 signal is not
detected at later time points, even though significant loss of NFL and ß-tubulin
immunoreactivity occurs at 48 hours. Pretreatment with intraperitoneally administered
calpain inhibitor leupeptin, which is continued throughout the survival period, does not
prevent NFL degradation 72 hours post-sciatic nerve transection. These findings led the
authors to suggest that calpains may not be directly responsible for cytoskeletal
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degradation in vivo. The stability of the calpain-cleaved spectrin fragment or whether
there was sufficient intra-axonal concentration of leupeptin is not known. Araújo Couto
and colleagues (2004) applied the calpain inhibitor, Mu-F-HPh-FMK, directly to the optic
nerve crush site in opossums. Ninety-six hours post-injury, there is statistically significant
increase in axons with preserved cytoskeleton (mean±SD: 76±3.7% versus 67±4.2%
nontreated injured) and reduction in degenerating axons with drug treatment. As Mu-FHPh-FMK also inhibits cathepsin L (product data sheet, Kamiya Biomedical, Seattle,
WA), the use of an inhibitor to both calpains and cathepsins limits experimental
interpretation. Based on these two studies, it is not clear if calpains are the causative
agents of Wallerian degeneration in vivo.
In 2005, Kerschensteiner and colleagues (2005) coined the term “acute axonal
degeneration” (AAD) to describe the rapid fragmentation of axons immediately proximal
and distal to the transection site. These investigators used transgenic mice that express
green fluorescent protein (GFP) in DRG axons traversing superficially through the spinal
cord. Within 5 minutes of transection, there is fragmentation and disintegration of 200300 µm of axon proximal and distal to the injury site. Application of a calpain inhibitor
cocktail to the site of transection is completely protective. Another study provides indirect
support for calpains by demonstrating that blocking Ca2+ entry after optic nerve crush
ameliorated AAD (Knöferle et al., 2010). Even though AAD is temporally and spatially
dissimilar to Wallerian degeneration, they may share similar molecular mechanisms.
Based on the entire body of evidence presented here, I conclude that calpains
may be important contributors to axonal pathology, particularly neurofilament
degradation. Axonal injury and degeneration is likely multifactorial, and may include Ca2+
dependent non-calpain mechanisms, the ubiquitin-proteasome system or autophagy
(Beirowski et al., 2010,; Knöferle et al., 2010; Zhai et al., 2003). The work presented in
16

this dissertation builds on these previous observations by showing a definitive causal
role of calpains in cytoskeletal degeneration.

B. Disruption of axonal transport and secondary axotomy after traumatic axonal injury
B.1. Overview of traumatic axonal injury
Axonal injury significantly contributes to blunt TBI severity and outcomes
(Gennarelli et al., 1982; Medana and Esiri, 2003). In the mammalian CNS, immediate
severing or transection of axons at the moment of trauma, known as primary axotomy, is
an irreversible process, and is thought to only occur at the most severe mechanical
strains (Maxwell et al., 1997). After blunt TBI, most of the injured axons are not torn at
the moment of trauma, but a biochemical cascade is triggered within axons, ultimately
disrupting their continuity (Jafari et al., 1997; Maxwell and Graham, 1997; Povlishock
and Katz, 2005; Povlishock et al., 1997; Saatman et al., 2003). The progression from
nondisruptively injured axons to overt axonal disconnection is termed secondary
axotomy. Injured axons display impaired axonal transport and neurofilament alterations.
After severe TBI in humans, axonal swellings due to the accumulation of organelles and
other cytoplasmic proteins are seen within 6 hours of injury (Christman et al., 1994;
Grady et al., 1993). There is also disruption of the ordered arrangement of
neurofilaments, and as early as 12 hours post-injury, axonal bulbs are apparent
(Christman et al., 1994). Axonal bulbs refer to swellings that have overtly disconnected
from the rest of the axon. As axonal swellings and neurofilament alterations are
potentially reversible or preventable, they are a major focus of TBI researchers.
Disruption of axonal cytoskeleton and transport after trauma has been studied
using a number of assays. Immunostaining for amyloid precursor protein (APP) and
nonphosphorylated neurofilament, both of which undergo anterograde transport, labels
17

axonal swellings and bulbs at presumably focal sites of disrupted transport. Exogenously
applied substances, such as horseradish peroxidase (HRP; Gennarelli et al., 1989;
Povlishock et al., 1983) and fluorogold (Ma et al., 2012; Saatman et al., 2003), or
overexpressed proteins like yellow fluorescent protein (Wang et al., 2011) have been
used to detect axonal transport disruption.
An attractive hypothesis is that microtubule loss impairs axonal transport
(Maxwell, 1996; McCracken et al., 1999; Saatman et al., 2003). There is a dramatic loss
of microtubules 15 minutes after optic nerve stretch in the guinea pig (Maxwell and
Graham, 1997). The number of microtubules returns to baseline by 2 hours at the
paranode and 4 hours at the node, but remains decreased for at least 24 hours at the
internode. Importantly, internodal axonal swellings containing significantly reduced
numbers of microtubules develops within 2 hours of injury.
Neurofilament alterations are another commonly used histologic marker of TAI.
All three neurofilament subunits have a central alpha-helical rod domain of about 300
amino acids, flanked by a lobular amino-terminal head and non alpha-helical carboxyterminal side-arm domains. When neurofilament polymerizes to form long filamentous
structures, the rod domains are normally masked by the phosphorylated sidearms.
Binding of the antibody RMO-14 to the rod domain of NFM suggests that proteolysis or
dephosphorylation of the sidearm has occurred (Büki et al., 2003; Maxwell et al., 1997;
Povlishock et al., 1997; Stone et al., 2001). The presumed corollary of RMO-14
immunolabeling on the ultrastructural level is neurofilament compaction, i.e. reduction of
interneurofilament distance. RMO-14 immunoreactivity is prominent in the corticospinal
tract and medial longitudinal fasciulus in animal models of DAI (Büki et al., 2003; Stone
et al., 2001). It has been suggested that neurofilament alterations may impair
axoplasmic transport (Christman et al., 1994; Smith and Meaney, 2000). However,
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RMO-14 immunoreactive axons in the corticospinal tract do not stain with APP nor have
evidence of organelle pooling, suggesting that neurofilament sidearm modifications may
not by itself impair axonal transport (Stone et al., 2001).

B.2. Role of calpains in traumatic axonal injury
The molecular mechanisms responsible for impaired axonal transport,
neurofilament alterations, and secondary axotomy have not been definitively established
but calpains may play a role, particularly in the CNS. Whether these same events occur
in the PNS is not as clear as injured PNS axons do not typically swell (Beirowski et al.,
2010). Axonal calpain activity has been reported to be elevated within minutes after
experimental TAI (Büki et al., 1999b; Saatman et al., 2003). Calpain activity measured
by Ab38 immunolabeling occurs in axons in the pyramidal tracts and medial lemnisci 15
minutes after head acceleration injury in rats (Büki et al., 1999b). Ab38 immunoreactivity
consistently colocalizes with RMO-14, suggesting that neurofilament modification may
be due to calpains. After optic nerve stretch in the mouse, an in vivo model that isolates
mechanical strain primarily to axons, calpain activity is detectable within axons 20-30
minutes post-injury.
Calpain inhibitor studies have provided more direct support for the causal role of
calpains in TAI pathology. A single 30 mg/kg IV dose of MDL-28170 30 minutes prior to
impact head acceleration injury in rats reduces APP and RMO-14 staining in the
corticospinal tract and medial longitudinal fasciculus 2 hours post-injury (Büki et al.,
2003). Longer-term protection is also achieved with a single 30 mg/kg IV dose of MDL28170. Given 30 minutes prior to fluid percussion injury, there is decreased APP labeling
and preservation of compound action potential in the corpus callosum up to 7 days after
injury (Ai et al., 2007). The calpain inhibitor N-acetyl-leu-leu-methioninal administered via
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continuous arterial infusion throughout the entire survival period reduces axonal
swellings and bulbs in the corpus callosum and other white matter tracts 24 hours after
cortical impact injury in the rat although quantification is not reported (Posmantur et al.,
1997). Transport disruption may be due to the loss of microtubules (Maxwell and
Graham, 1997), and may be partly due to calpain proteolysis of tubulin and MAPs
(Billger et al., 1988; Fischer et al., 1991; Johnson et al., 1989). Care must be taken when
interpreting findings from global TBI models. In these models, it is often difficult to tease
apart primary versus secondary injury to axons. Theoretically, the drug may directly
protect non-axonal structures, which, in turn, may reduce the secondary injury seen in
axons. The work presented in this dissertation builds on these previous observations by
showing a definitive causal role of calpains in axonal transport disruption in an animal
model that isolates mechanical strain primarily to axons.

B .3. Commonalities and differences between Wallerian degeneration and TAI
Calpains may directly contribute to cytoskeletal alterations and degeneration, and
transport disruption after nerve transection and TAI. The duration and degree of
elevation of calpain activity may be important in shaping the axonal pathology seen.
Immediately after nerve transection, there is localized Ca2+ elevation that normalizes
within a few minutes (Knöferle et al., 2010). This transient Ca2+ rise activates calpains,
which may be responsible for AAD. However, Ca2+ homeostasis is quickly restored after
a few minutes. During the latency period, transected axons may experience focal
disruption of Ca2+ homeostasis, resulting in axonal swellings, the signature pathology of
TAI. After in vivo optic nerve transection, swellings distal to the transection site are seen
as early as 4 hours in the mouse (Hasegawa et al., 1988) and 2 days in the rat (Meller
et al., 1994). I propose that the abrupt end to the latency period coincides with a
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catastrophic yet unexplained failure to maintain intra-axonal Ca2+ homeostasis, resulting
in sustained and robust calpain activity and GDC.
TAI results in immediate Ca2+ elevations and pathologic calpain activity in
localized regions of the axon likely causing transport disruption and swelling formation.
The mechanism by which axonal swellings transition into bulbs is not known. Once
axons become disconnected, Wallerian degeneration of the disconnected distal axon
ensues. In addition to calpains, there may also be other axon degeneration pathways
common to Wallerian degeneration and TAI. There may be Ca2+ dependent non-calpain
pathways that are important in Wallerian degeneration and TAI (Staal et al., 2010; Zhai
et al., 2003). In contrast, apoptotic mechanisms have been implicated in TAI (Büki et al.,
2000; Büki and Povlishock, 2006; Chen et al., 2004; Stone et al., 2002) but it is not likely
to be important in degeneration of the transected axon (Finn et al., 2000; Kilinc et al.,
2010; Schoenmann et al., 2010; Whitmore et al., 2003). Inhibition of the ubiquitinproteasome system protected transected axons in vitro and in vivo (Zhai et al., 2003),
but accelerated progression to secondary axotomy after in vitro axonal stretch injury
(Staal et al., 2009).

B.4. Intra-axonal sources of Ca2+ driving calpain activation
As calpains absolutely require elevated Ca2+ for activity, the source of this intraaxonal Ca2+ has garnered much scientific interest. Some studies implicate intracellular
Ca2+ stores, while others extracellular Ca2+. Because of the complexity of manipulating
Ca2+ in vivo, much of the work has been performed in vitro. Staal and colleagues (2007)
deformed axonal bundles from rat cortical neurons using a fluid pulse, generating a
transient 1-6% increase in original axon length. The axolemma remains impermeable to
a 570 kDA molecular weight (MW) tracer for up to one hour post-injury. There is an
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immediate rise in intra-axonal Ca2+ even though axons are bathed in Ca2+-free bath
(Staal et al., 2010). The authors concluded that the source of intra-axonal Ca2+ is
principally from intracellular stores.
In a model where neurites from rat cortical neurons or a human neuronal cell line
are stretched 70-75% beyond their initial lengths, a rise in intra-axonal Ca2+ is seen
immediately, but can be blocked if extracellular Ca2+ or Na+ is removed or if neurons are
pretreated with inhibitors to voltage-gated Na+ or Ca2+ channels or the Na+-Ca2+
exchanger (Iwata et al., 2004; Wolf et al., 2001). Na+ entry through mechanically
sensitive Na+ channels may trigger an increase in intra-axonal Ca2+ via opening of
voltage-gated Ca2+ channels or reversal of the Na+-Ca2+ exchanger. In this model, there
is also no uptake of the 570 kDA tracer (Smith et al., 1999). These three studies
implicate ion channels, and not the creation of traumatic defects (mechanoporation) of
the axolemma, as the mechanism of extracellular Ca2+ entry.
In vivo studies have added further complexity. Moderate fluid percussion injury
(>2.0 atm), but not mild (1.5 to 2.0 atm), results in axolemmal permeability to HRP as
early as 5 minutes after injury (Pettus et al., 1994). Post-injury calpain activity may
further worsen axolemmal permeability in a feed forward spiral. Rats treated with MDL28170 prior to impact head acceleration injury have improved axolemmal integrity in the
corticospinal tract 2 hours post-injury (Czeiter et al., 2009). The authors proposed that
this might be due to a reduction in calpain-mediated proteolysis of spectrin, which is
important for membrane stability.
Studies of ischemic and hypoxic axons have also provided valuable insights
about potential sources of intra-axonal Ca2+. Rise of intra-axonal Ca2+ in ex vivo optic
nerves undergoing simulated ischemia is due to both extracellular Ca2+ and internal
stores (Nikolaeva et al., 2005; Stys, 2005). During chemical inhibition of energy
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metabolism in dorsal root myelinated axons or exposure of optic nerves to anoxia ex
vivo, the Ca2+ overload occurs via reversal of Na+-Ca2+ exchanger, driven by axonal Na+
accumulation through voltage-gated Na+ channels (Petrescu et al., 2007; Stys and
Lopachin, 1998). L-type and N-type Ca2+ channels have also been implicated (Brown et
al., 2001; Fern et al., 1995). The source of the intra-axonal Ca2+ rise appears to depend
on the injury and the model system, so directly targeting Ca2+ elevation may require
different therapeutic interventions.

C. Calpains may contribute to the disruption of specialized electrical domains,
presynaptic terminals and electrophysiological function
C.1. Overview of the axolemmal cytoskeleton and specialized electrical domains
Actin and spectrin are major components of the axolemmal cytoskeleton, and
contribute to the formation and stability of specialized electrical domains (Fig. 1; Isayama
et al., 1991; Yang et al., 2004). Spectrins are comprised of α- and ß-subunits, and have
binding sites for actin, ankyrin, and ion channels (Bennett and Baines, 2001). The α- and
ß-subunits associate laterally to form antiparallel heterodimers, and the heterodimers, in
turn, are assembled head-to-head to form heterotetramers. In humans, there are two αsubunits (αI and αII), 4 ß-subunits (ßI, ßII, ßIII, and ßIV), and a ß-H subunit (also
referred to as ßV). αII/ßII is located diffusely across the length of the axons but,
depending on the nerve, can be enriched at paranodes and juxtaparanodes (Bennett
and Baines, 2001; Ogawa et al., 2006), and in presynaptic compartments (Goodman,
1999; Isayama et al., 1991; Schmitz, 2001).
Action potential initiation, saltatory conduction, and synaptic transmission require
specialized structures at the AIS, nodes and synaptic terminal, respectively. The voltagegated Na+ channels, Nav1.2 and Nav1.6, are localized to the mature AIS (Debanne et
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al., 2011; Rasband, 2011). AnkyrinG (ankG) and ßIV spectrin link membrane proteins to
the underlying actin cytoskeleton. ßIV spectrin is unique to the AIS and nodes (Schafer
et al., 2009; Yang et al., 2004). Mature nodes share similar cytoskeleton organization as
the AIS, except they lack Nav1.2 (Rasband, 2011; Schafer et al., 2009). AIS, nodes, and
juxtaparanodes are enriched with K+ channels and cell adhesion molecules (CAMs). The
two main CAMs at the AIS and nodes are neurofascin-186 and NrCAM, while the
juxtaparanodes contain Caspr2, TAG-1 and ADAM22. In unmyelinated axons, which
lack nodal domains, action potential propagation is supported by a homogenous
distribution of Nav1.2 (Debanne et al., 2011).

C.2. Calpain substrates in the axolemma and axolemmal cytoskeleton
As discussed earlier, the proteolysis of αII-spectrin is a commonly used, sensitive
and specific way to assay for in vivo calpain activity (Roberts-Lewis et al., 1994).
Proteolysis of αII-spectrin renders its actin binding and crosslinking activity
downregulatable by calmodulin (Harris and Morrow, 1990). The ß subunits are also
calpain substrates (Löfvenberg and Backman, 1999; Schafer et al., 2009), and
proteolysis of both subunits permanently impairs spectrin binding to actin regardless of
calmodulin (Harris and Morrow, 1990). Disruption of the structure and function of these
specialized electrical domains may be due to calpain proteolysis of the underlying
axolemmal cytoskeleton.
Intramembrane proteins that are calpain substrates include Nav1.2, L-type Ca2+
channel, and Na+-Ca2+ exchanger (NCX). Calpains cleave the Nav1.2 α-subunit at two
predicted sites: within the I-II loop and II-III loop (von Reyn et al., 2009). There is
possibly a third cleavage site but this is much less certain. The α-subunit contains the
binding site for tetrodotoxin, the selectivity filter, the channel pore, and the structural
24

elements responsible for activation and inactivation. Inactivation refers to the process by
which an open Na+ channel can close even in the presence of a maintained
depolarization. After proteolysis, the majority of the channel stays in the membrane but
the functionality of the remaining cleaved channel is not known (von Reyn et al., 2009).
Iwata and colleagues (2004) suggested that proteolysis may prevent the inactivation of
the channel. Isolated stretch of neurites in cortical cultures causes an immediate rise in
intra-axonal Ca2+ that is dependent on Na+ influx (Iwata et al., 2004). Pretreatment with a
protease inhibitor cocktail, which inhibits calpains among others, blocks the secondary,
but not initial, rise in Ca2+. The authors proposed a feedforward pathway, where
proteolysis of the Na+ channel results in loss of channel inactivation and more Na+ influx,
which drives the secondary Ca2+ rise.
Class C and D L-type Ca2+ channels have a homogenous distribution on
myelinated optic nerve axons (Brown et al., 2001). These channels directly contribute to
the intra-axonal rise of Ca2+ in simulated ischemia of optic nerves (Brown et al., 2001;
Fern et al., 1995). In hippocampal neurons exposed to NMDA, the long form of the class
C α1 subunit (210-220 kDA) is proteolyzed by calpains at its C-terminal domain,
removing an estimated 250-300 amino acid residues (Hell et al., 1996). Work with Cterminal truncation mutants of rabbit cardiac α1 subunits suggests that loss of the Cterminus results in enhanced activation of the channel in response to depolarization (Wei
et al., 1994).
In normal physiology, the Na+-Ca2+ exchanger (NCX) couples Ca2+ extrusion to
Na+ influx. The relative expression of the three isoforms (NCX1, NCX2, and NCX3) on
axons and presynaptic terminals has not been firmly established (Lee et al., 2007;
Minelli et al., 2007; Papa et al., 2003; Steffensen et al., 1997). In ischemia and isolated
stretch of neurites, increased intracellular Na+ concentration may drive the NCX to work
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in reverse mode, thus contributing to the rise in intracellular Ca2+ (Iwata et al., 2004;
Petrescu et al., 2007; Stys and Lopachin, 1998). After brain ischemia and in glutamate
treated neuronal cultures, NCX3 proteolysis is mediated by calpains (Bano et al., 2005).
NCX1, but not NCX2, is also proteolyzed after brain ischemia but the causative agent is
not known. One of the calpain cleavage sites of NCX3 is in close proximity to the highaffinity Ca2+ binding regulatory domain, which is essential for modulating transport
activity. NCX3 proteolysis results in loss of function, which is directly responsible for the
excitotoxic death of cultured neurons.

C.3. Evidence of calpain involvement in the disruption of specialized domains
Evidence from various injury models suggests that calpains may be causative
agents for the structural disruption of specialized electrical domains in axons. Disruption
of the AIS after middle cerebral artery occlusion (MCAO) and in vitro oxygen glucose
deprivation results from calpain proteolysis of ßIV spectrin and ankG (Schafer et al.,
2009). AIS disruption is also seen 5 days after optic nerve crush. AIS disruption, which
could be ameliorated by MDL-28170 or calpastatin overexpression, is irreversible,
results in loss of neuronal polarity and is independent of cell death. For unclear reasons,
MCAO disrupts the organization of AIS but not nodes even though they share a similar
composition (Schafer et al., 2009). In an ex vivo model of anti-ganglioside antibodymediated motor nerve terminal injury, the ultrastructure of the NMJ presynaptic
components is preserved with pharmacologic calpain inhibition (O'Hanlon et al., 2003).
In addition to the disruption of axolemmal membrane architecture in various
injury models, axonal electrical and synaptic functions are also impaired. Optic nerve
stretch results in abnormalities in visual evoked potential latency and amplitude several
minutes after injury (Tomei et al., 1990), while fluid percussion injury causes
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abnormalities in compound action potentials evoked in the corpus callosum 3 hours
post-injury (Reeves et al., 2005). Compound muscle action potential (CMAP) is
essentially lost 17 hours after sciatic nerve crush in mice (Moldovan et al., 2009). In spite
of the many known calpain substrates that are critical for electrical function,
pharmacologic calpain inhibitors do not protect action potential propagation after nerve
injury (Jiang and Stys, 2000; Stys and Jiang, 2002). Even though calpain inhibition
protects against neurofilament and spectrin breakdown in optic nerves exposed to ex
vivo anoxia or oxygen-glucose deprivation, there is no electrophysiological protection
(Jiang and Stys, 2000; Stys and Jiang, 2002). In ex vivo muscle preparations, the
calpain inhibitor AK295 preserves immunoreactivity of Nav1.6, ankyrin G, Caspr, and
neurofascin at the nodes, but does not afford protection of perineural currents or
compound action potential in a model of anti-GD1a antibody directed complement
activation (McGonigal et al., 2010). The authors suggested that the failure of the
axolemma, when punctured by membrane attack complexes, to maintain ionic
homeostasis may be the critical factor in mediating axonal conduction block in this
model. The applicability of these findings to TAI or injury models, where the axolemma
reseals or is not compromised, is not clear.

VI. Thesis rationale
Axonal injury and degeneration contribute to the morbidity and mortality of many
human diseases, including TBI, SCI, cerebral ischemia, neurodegenerative diseases,
and PNS disorders. These seemingly disparate disorders may share common molecular
injury mechanisms. One such mechanism may be pathologic calpain activity within
axons. Previous studies using various injury models have suggested that calpains may
play a universal role in axonal injury and degeneration. However, definitive evidence for
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a causal role of calpains in cytoskeletal degradation and axonal functional impairment is
still required. I used two models of axonal injury, nerve transection and mechanical
stretch of axons, to cause different pathologies in axons, in particular GDC and
retrograde transport disruption. I hypothesized that calpains are causally responsible for
both. Defining potentially universal mechanisms by which axons are injured may help
our understanding of various human diseases in which axonal and synaptic dysfunction
and degeneration are prominent.
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Figure 1.1

Fig. 1.1. Schematic of a myelinated axon. Proteolysis of known calpain substrates within
the axon initial segment (AIS) and nodes (A) and axon cytoskeleton (B) may contribute
to the structural and functional disruption seen in injured axons. The molecular
composition of AIS and nodes is similar. Represented locations of proteins are not
exhaustive. Cav, Ca2+ channel, Nav, Na+ channel; NCX, Na+-Ca2+ exchanger.
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CHAPTER 2:
Role of calpains in axonal and synaptic
degeneration in the central and peripheral
nervous systems
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Abstract
In both the central nervous system (CNS) and peripheral nervous system (PNS),
transected axons undergo Wallerian degeneration. Early pathology includes denervation
of the synapse, failure of synaptic transmission, and granular disintegration of the axonal
cytoplasm (GDC). The evidence that the Ca2+-dependent protease calpains contributes
to GDC is not compelling. To test the hypothesis that calpains play a causal role in
axonal and synaptic degeneration in vivo, we studied transgenic mice that overexpress
human calpastatin (hCAST), an endogenous calpain inhibitor, in optic and sciatic nerve
axons. Five days after optic nerve transection and 48 hours after sciatic nerve
transection, there was robust neurofilament light chain proteolysis in wild-type controls
that was prevented in hCAST transgenic mice. In addition, there was significant
morphological protection of sciatic nerve axons after transection in hCAST expressing
mice (90.2±6.5% versus 18.3±5.3% p<0.0001). There was also a trend towards
morphological protection in optic nerves (p=0.03). Although hCAST expression
preserved the morphological integrity of neuromuscular junctions after sciatic nerve
transection (71.3±10.3% of NMJ had greater than 50% but not complete innervation
versus 11.8±7.9% wild-type, p<0.001), there was no improvement in compound muscle
action potential amplitudes (p=0.51). These results provide direct evidence that calpains
are responsible for the structural degeneration of axons and synapses seen in Wallerian
degeneration.
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Introduction
In 1849, Augustus Waller made the seminal observation that after nerve
transection, the distal portion undergoes progressive degeneration (Waller, 1850).
Wallerian degeneration occurs in both the central nervous system (CNS) and peripheral
nervous system (PNS). After transection, there is a latency period of varying lengths,
when the distal nerve is morphologically normal and electrically excitable (Wang et al.,
2012). Early pathological changes include denervation of the pre-synaptic terminal,
failure of synaptic transmission, and granular disintegration of the cytoplasm (GDC), in
which the organelles and cytoskeletal components appear to disintegrate (Miledi and
Slater, 1970; Okamoto and Riker, 1969). Both CNS and PNS axons undergo GDC but a
subpopulation of transected CNS axons alternatively undergoes “dark” degeneration,
where the axoplasm fills with electron-dense material that obscures the cytoskeleton
(Bignami et al., 1981; George and Griffin, 1994; Marques et al., 2003).
Calpains are a family of Ca2+-dependent nonlysosomal proteases, and have
been implicated in axonal degeneration. Their physiologic roles include cytoskeletal
remodeling, cell-cycle regulation, signal transduction, vesicular trafficking, apoptosis,
and necrosis (Zatz and Starling, 2005). The two ubiquitous calpains, µ- and m-calpain,
are heterodimers consisting of 80 kDa catalytic subunits that are ~50% identical in their
amino acid sequence, and a common 30 kDa regulatory subunit. The major functional
difference between µ- and m-calpain is the in vitro Ca2+ concentration required for halfmaximal activity, 3-50 µM and 400-800 µM, respectively (Goll et al., 2003). Calpastatin,
another member of the calpain family, is an endogenous inhibitor completely specific for
calpains and does not inhibit any other protease (Goll et al., 2003).
Evidence linking calpains to Wallerian degeneration primarily comes from in vitro
studies using pharmacologic inhibitors. Pharmacologic calpain inhibitors prevent neurite
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fragmentation and disappearance, or loss of neurofilament immunostaining after neurite
transection of dorsal root ganglia (DRG) and sympathetic superior ganglia (SCG)
explants (Finn et al., 2000; George et al., 1995; Wang et al., 2000; Zhai et al., 2003). All
pharmacologic calpain inhibitors, however, inhibit other proteases (Goll et al., 2003).
Two in vivo studies examining protection of transected CNS and PNS axons with calpain
inhibitors were inconclusive (Araújo Couto et al., 2004; Glass et al., 2002).
The present study seeks to expand our understanding of the role of calpains in
axonal and synaptic degeneration in the adult CNS and PNS. We hypothesized that
specific calpain inhibition within axons would provide biochemical, morphological and
functional protection after axonal transection in vivo. Previous in vitro studies must be
interpreted cautiously as explants usually consist of developmentally young neurons
lacking the complex supporting structures seen in vivo. In addition, earlier studies relied
on pharmacologic calpain inhibitors. Therefore, our strategy utilized adult transgenic
mice that overexpress human calpastatin (hCAST) within the axons of the optic and
sciatic nerves. Mechanistic insight into axonal and synaptic degeneration is likely
relevant to many acquired and inherited disorders, such as traumatic brain injury, spinal
cord injury, neurodegenerative diseases, and demyelinating and hereditary
neuropathies.
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MATERIALS AND METHODS
All animal procedures were performed in accordance with NIH guidelines for the care
and use of laboratory animals and were approved by the Institutional Animal Care and
Use Committee at the Universities of Pennsylvania and Kentucky.

Generation of hCAST transgenic mice
Mice overexpressing hCAST under the primarily neuronal prion promoter were
created on a FVB/N background. Mice were maintained as heterozygotes by breeding
purchased wild-type FVB/N females (Harlan Labs, Indianapolis, IN) with hCAST
transgenic male heterozygotes. For experimental procedures, adult transgenic and wildtype littermates (4-6 months of age) were used.

Immunohistochemistry of nerves and brain
Mice were anesthetized with ketamine and xylazine. They were transcardially
perfusion fixed with 1x PBS followed by 4% paraformaldehyde in 0.1 M phosphate buffer
(PB, ph 7.4). Optic and sciatic nerves were removed and postfixed in perfusate at 4°C
for 1 hour, then cryoprotected in 30% sucrose. Brains were taken from non-perfused
animals, and postfixed in 4% paraformaldehyde in 0.1 M phosphate buffer at 4ºC for 6
hours prior to cryoprotection in sucrose. Ten µm thick longitudinal and cross-sections of
nerves and 20 µm thick coronal sections of brain from wild-type and hCAST transgenic
mice were cut on the cryostat. Brain and nerve sections were blocked in 3% normal goat
serum and 0.1% triton in 1x PBS for 30 min at room temp. Nerve sections were
incubated with antibodies targeting neuron-specific class III ß-tubulin (Tuj1; 1:2000,
Covance, Emeryville, CA) or calpastatin (sc-20779; 1:250; Santa Cruz Biotech, Santa
Cruz, CA) in blocking solution at 4°C overnight. Brain sections were incubated with
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antibodies targeting neuron-specific class III ß-tubulin (PRB-435P; 1:5000, Covance) or
human calpastatin (MAB3084; 1:1000; Millipore, Billerica, MA). The following day, the
sections were washed with 1x PBS, incubated with alexa secondary antibodies (Life,
Grand Island, NY) for 1 hour at room temp, rinsed in PBS, and coverslipped with
Fluoromount G (Electron Microscopy Sciences, Hatfield, PA).

Ex vivo calpain inhibition assay of cortical homogenates
Under ketamine and xylazine anesthesia, wild-type and hCAST transgenic mice
were decapitated and the brain removed and placed on ice. The cortex was isolated and
sonicated on ice in 25 mM hepes, 1 mM EDTA, 5 mM B-mercaptoethanol, and 0.1%
CHAPS (pH 7.4). The homogenates were frozen, so that all samples could be assayed
in triplicate on the same microtiter plate. Protein concentration was determined using the
Bradford assay. Reactions for calpain activity assay contained 100 µg of cortical
homogenate, 5 nM calpain 1 (EMD) and 200 µM Suc-Leu-Tyr-MNA (MP Biomedicals,
Solon, OH) in a total volume of 200 µl. The room temp reaction was started by adding
CaCl2 to a final concentration of 5 mM. Time-dependent substrate hydrolysis was
measured on a microplate reader (Turner Biosystems, Sunnyvale, CA; 365 nm
excitation, 410-460 nm emission).

In vitro calpain digest of optic and sciatic nerves
Optic and sciatic nerves were removed from 3 wild-type FVB/N mice, pooled, and
sonicated on ice in 25 mM HEPES, 1 mM EDTA, 5 mM B-mercaptoethanol, and 0.1%
CHAPS (pH 7.4) with phosphatase inhibitor cocktail (Roche, Indianapolis, IL). Protein
concentration was determined using the Bradford assay. Reactions contained 1.9 µg/µl
of nerve homogenates and some combination of 1 µM calpastatin peptide (EMD,
35

Gibbstown, NJ), 100 nM human erythrocyte µ-calpain (EMD), or 100 nM recombinant mcalpain (EMD). The room temp reaction was started by adding CaCl2 (or equal volume of
water) to a final concentration of 5 mM. Reactions were stopped at designated times by
adding 2x loading buffer and heating to 95ºC for 5 min.

Unilateral optic nerve transection
Adult mice were anesthetized with ketamine (100 mg/kg intraperitoneal, IP) and
xylazine (10 mg/kg IP), pretreated with buprenorphine (0.05 mg/kg IP) and placed on a
heating plate. Bupivacaine anesthetic drops were applied to the eyes. Under a binocular
operating microscope, the conjunctiva was separated from the sclera superiorly and the
optic nerve exposed by blunt dissection. The optic nerve was transected ∼1 mm behind
the globe using Vannas spring scissors (Fine Science Tools, Foster City, CA).
Erythromycin ophthalmic ointment was applied to both eyes. Mice received
buprenorphine (0.05 mg/kg IP) every 12 hours for up to a total of 4 additional doses.

Unilateral sciatic nerve transection
Sciatic nerve transection was performed 72 hours after optic nerve transection.
The lower back was shaved and cleaned with betadine. The skin was incised then the
sciatic nerve was exposed by blunt dissection and transected at the internal obturator
tendon using Vannas spring scissors. For longer survival times, a 10-0 ligature was
applied to the proximal stump, and sutured to the surrounding tissue to prevent axonal
growth into the distal segment. The skin was then sutured. Mice received buprenorphine
every 12 hours for up to a total of 4 additional doses. For electrophysiological and NMJ
experiments, the animals did not receive optic nerve transection.

36

Ultrastructural analysis of nerves
Anesthetized mice were transcardially perfusion fixed with 2% paraformaldehyde
and 2% glutaraldehyde in 0.1 M PB (pH 7.4). The nerves were quickly removed, then
postfixed in perfusate solution for at least 4 hours at 4°C. Nerves were osmicated and
dehydrated. They were treated twice with propylene oxide for 5 min, incubated
sequentially with Embed 812:propylene oxide mixtures (1:1 and 2:1) and pure Embed
812 mixture (Electron Microscopy Sciences) overnight. Tissues were then embedded in
fresh Embed 812 mixture at 60°C for 48 hr. Cross-sections were cut at a thickness of 1
µm, stained with toludine blue and examined by light microscopy.
Nerve cross-sections were imaged using a FEI Tecnai 12 electron microscope
equipped with a Gatan 895 US1000 2k x 2k CCD camera. Optic nerves were analyzed
0.5 mm from the optic chiasm, while sciatic nerves were analyzed 8.5 mm distal to
transection. Systemic sampling of the nerve cross-sections was previously described in
Ma et al. (2009) with minor modifications. For optic nerve scoring, images were captured
at 3200x mag at 40 µm increments across and down the nerve. Sciatic nerve images
were captured at 3200x mag at 30 µm increments.

Optic nerve scoring (5 days post-transection)
Using Adobe Photoshop (San Jose, CA), a counting frame (as described by
Gundersen, 1977) was overlaid on each image, and a blinded observer counted the
number of intact myelinated axons with preserved cytoskeleton. Axons were counted as
intact if (1) visible axoplasm had cytoskeletal preservation, and (2) <25% of the crosssectional area was filled with electron-dense material (“dark” degeneration). Myelin
integrity was not a consideration as intra-axonal calpain inhibition is unlikely to directly
affect myelin. Unmyelinated axons make up only a small fraction of total optic nerve
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axons (<1%) in the adult rodent (Sugimoto et al., 1984), and were not scored. The area
of the optic nerve cross-section was determined using NIH imageJ, and numbers were
reported as total axons per nerve. Approximately 2% of the nerve cross-section was
scored.

Sciatic nerve scoring (48 hours post-transection)
Because sciatic nerve myelinated axons are significantly larger than optic nerve
axons, very few axons are entirely in view at 3200x mag. Therefore, when sampling the
sciatic nerve cross-section at 40 µm increments, a myelinated axon was selected for
scoring based on proximity to a superimposed point. That axon was moved to the center
of the viewing frame and imaged. This process was repeated until the entire crosssectional area was systematically sampled, as described above. Using DigitalMicrograph
(Gatan, Pleasanton, CA), only myelinated axons were scored. A myelinated axon was
considered intact if there was uniform, regularly spaced cytoskeleton in at least 50% of
the visible axoplasm. Neither myelin integrity nor axoplasmic shrinkage was considered
in the scoring of axons. The percent of myelinated axons that were intact is reported.
About 80-140 myelinated axons were scored per sciatic nerve.

Scoring of NMJ innervation
After euthanasia, mice were decapitated, and the extensor digitorum longus
(EDL) was carefully dissected from the leg and fixed in 4% paraformaldehyde in 0.1 M
PB (pH 7.4) for 20 minutes, followed by 1x PBS rinses. Immunolabeling for NMJs in
whole mount muscle preparation was performed as described by Bauder and Ferguson
(in press) using antibodies targeting neurofilament (SMI-312R; 1:10000, Covance) and
synaptic vesicles (SV2; 1:1000; Developmental Studies Hybridoma Bank, Iowa City, IA),
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and TRITC conjugated α-bungarotoxin (1:200; Sigma-Aldrich, St Louis, MO). The
antibodies targeting neurofilament and synaptic vesicles were visualized with a
fluorescein conjugated goat anti-mouse secondary antibody (Jackson ImmunoResearch,
West Grove, PA). As neurofilament is not present in the NMJ, immunoreactivity at the
NMJ was due to SV2 labeling. Neurofilament immunoreactivity was used to confirm
antibody penetration into muscle tissue. Approximately 125-150 NMJs per muscle were
scored by a blinded observer. NMJ innervation (percentage coverage of α-bungarotoxin
by SV2 immunoreactivity) were visually estimated by a blinded observer and classified
as (1) complete, (2) >50% but not complete, (3) <50% but not absent, and (4) absent.

Electromyography
Fourteen hours after unilateral sciatic nerve transection, electromyography
(EMG) was performed as described by Osuchowski et al. (2009). Mice received IP
ketamine and xylazine and were placed on a heating plate. Rectal temperature was
maintained >35ºC. For stimulation, 1-cm stainless steel electrodes were placed
subdermally: the anode just lateral to the midline, with the tip inserted 1 mm caudal to
the tail-base and advanced parallel to the spine, and the cathode ~3 mm lateral and
parallel to the anode. One-cm subdermal needles inserted in the proximal thigh and into
the heel served as the ground and reference electrodes, respectively. Each animal was
simulated with incremental impulse intensity until a maximal and artifact-free compound
muscle action potential (CMAP) motor response was evoked. Recordings were obtained
using a 9.5-mm gold plated ear clip electrode (Electrode Store, Enumclaw, WA). The
electrode was coated with an electrode gel and placed over the distal foot. This location
likely resulted in recordings from multiple small foot muscles. Manipulating the electrode
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on the foot was performed to ensure maximal CMAP. Measurements were made for
both legs using a Nicolet/VIASYS Viking Quest machine.

Processing of nerves for western blot
Under ketamine and xylazine anesthesia, mice were decapitated. The optic
nerve, after discarding the proximal ∼0.5 mm (transection site), was sonicated in 50 mM
tris (pH 7), 150 mM NaCl, 1% triton, and 2 mM EGTA. Approximately 8.5 mm of the
sciatic nerve distal to the transection was removed from the body. The proximal ∼1 mm
(transection site) was discarded, and the remaining was sonicated in 50 mM tris (pH
7.5), 1% SDS, and 2 mM EDTA. The homogenate was centrifuged at 16100 g, and the
pellet discarded. Buffers contained protease inhibitor cocktail (Roche, Indianapolis, IN).
Corresponding lengths of contralateral nerves were used as uninjured controls.

Western blot
Protein concentration was quantified using Bradford assay. Proteins were
separated using SDS-PAGE on a 4-20% tris-glycine gel, transferred to nitrocellulose
membrane, and probed for neurofilament light (NFL; PRB-574C; 1:20000; Covance),
calpastatin (sc-20779; 1:1000), or glyceraldehyde 3-phosphate dehydrogenase
(GAPDH; PA1-988; 1:1000; Thermo Scientific, Rockford, IL). Blots were visualized with
enhanced chemiluminescence (HRP-conjugated secondary antibodies and enhanced
chemiluminescence substrate from Perkin Elmer, Waltham, MA). Blots were then rinsed,
and amido black staining was performed for loading control.

Statistical analysis
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Student’s t-tests were used to compare the slopes (fluorescence over time)
obtained in the CAST activity assay and to compare wild-type and transgenic injured
muscle for NMJ innervation. A p-value < 0.05 was considered statistically significant. In
all other analysis, ANOVA in repeated measures was performed. A p-value <0.05 for
main effects and <0.2 for the interaction spaces were considered statistically significant.
Pairwise comparisons were specified a priori and were accomplished using the t-test
with pooling of the variance. Significance levels for pairwise comparisons were adjusted
for by using the Bonferroni correction. There were three pre-planned comparisons:
uninjured wild-type versus transgenic, injured versus uninjured wild-type, and injured
wild-type versus injured transgenic. For these 3 pairwise comparisons a p<0.017 was
considered significant. Data are presented as means and standard deviations. All data
were analyzed using SAS statistical software (version 9.2, SAS Institute, Cary NC).
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RESULTS
Characterization of hCAST transgenic mice
We first characterized expression of the hCAST protein in central and peripheral
nerves by performing western blots of cortical, optic nerve, and sciatic nerve
homogenates. There was high expression of hCAST in all three tissues from hCAST
transgenic mice but not in tissues from their wild-type littermates (Fig. 1A). We then
performed immunohistochemistry to confirm our western blot results and further
characterize calpastatin (CAST) localization. Overexpressed CAST was detectable in
cortical neurons and neuropil, and optic and sciatic nerve axons (Fig. 1B).
The functionality of the expressed hCAST was assessed using a fluorogenic
substrate microplate assay (Fig. 1C). The proteolysis of Suc-Leu-Tyr-MNA resulted in
increasing fluorescent signal. We compared cortical homogenates from transgenic mice
with their wild-type littermates. Homogenates from hCAST mice robustly inhibited
exogenous calpain activity (p<0.0001). Omitting the fluorogenic substrate or CaCl2
resulted in no increase in fluorescence over time. Omitting exogenous calpain resulted in
a slight increase in fluorescence only in wild-type homogenates, likely due to
endogenous calpains (data not shown). In summary, hCAST was robustly expressed in
cortex, and optic and sciatic nerve axons, and overexpressed hCAST retained its ability
to inhibit calpain.

In vitro calpain digest of optic and sciatic nerves yields unique neurofilament
fragments
To determine whether the levels of hCAST overexpression adequately inhibited
axonal calpains, we searched for a unique “signature” of intra-axonal calpain activity. We
sought to identify a substrate in nerves that was present exclusively within axons and
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that generated stable proteolytic fragments when cleaved by calpains. This would make
it possible to measure both loss of intact protein and accumulation of the reaction
product. Loss of intact neurofilaments, which are well-known calpain substrates, is a
commonly used outcome measure for axonal degeneration (Glass et al., 2002). We
investigated NFL (Fig. 2). Calpain activity is recognized by both its absolute dependence
on Ca2+ and inhibition by CAST. Unlike all pharmacologic inhibitors, CAST is completely
specific for calpains and does not inhibit proteases from other families (Glass et al.,
2002). Using an antiserum against full-length recombinant mouse NFL, we identified
multiple fragments in calpain digests of optic and sciatic nerves from wild-type mice.
Endogenous calpain activity resulted in time-dependent loss of intact NFL and
generation of a ∼55 kDA fragment. Both the loss of intact and generation of the ∼55 kDA
fragment was completely blocked by 1 µM CAST peptide. The addition of either
exogenous µ- or m-calpain (5 nM) accelerated the loss of intact NFL and generated the
∼55 kDA fragment as well as several lower molecular weight fragments, notably at ∼22
and ∼40 kDA.

Time course of axonal degeneration after optic and sciatic nerve transection
Our next step was to determine the optimal time point in vivo to compare axonal
degeneration in the CNS and PNS in hCAST versus wild-type mice. We performed
unilateral transection of optic and sciatic nerves in wild-type mice, and sacrificed them at
predetermined intervals. NFL western blot demonstrated significant loss of intact NFL 5
days after optic nerve transection and 48 hours after sciatic nerve transection (Fig. 3).
The NFL fragments generated are of similar sizes as those seen in the in vitro calpain
digest of nerve homogenates. The ∼22 and ∼40 kDa fragments were the most
prominent. The ∼55 kDa fragment was not consistently seen in degenerating optic or
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sciatic nerves, and may represent a less stable transition fragment. Morphological
analysis by electron microscopy confirmed significant axonal degeneration 5 days and
48 hours after optic and sciatic nerve transections, respectively (Fig. 5). Therefore, we
chose these time points to measure the effect of hCAST overexpression.

Biochemical effect of hCAST on CNS and PNS axonal degeneration
Our next experiment was to determine if hCAST overexpression can block NFL
proteolysis and the generation of the ∼22 and ∼40 kDa fragments. Human CAST
transgenic mice and their wild-type littermates underwent unilateral optic nerve
transection, followed by unilateral sciatic nerve transection 72 hours later. This strategy
made the most efficient use of animals, and transecting optic nerves prior to sciatic
nerve transection did not affect NFL proteolysis in sciatic nerves (data not shown). Five
days and 48 hours after optic and sciatic nerve transections, respectively, mice were
sacrificed and fresh nerve tissue harvested for analysis. There was no difference in
intact NFL levels between wild-type and hCAST mice in uninjured optic (p=0.21) and
sciatic nerves (p=0.60). There was significant loss of intact NFL and generation of the
∼22 and the ∼40 kDa NFL fragments after optic and sciatic nerve transections in wildtype mice. However, hCAST overexpression protected against NFL proteolysis in
transected optic and sciatic nerves. Five days after optic nerve transection, there was a
45.6±25% loss of intact NFL in wild-type mice (p=0.005). There was preservation of
intact NFL (p=0.007) and reduction in the generation of both the ∼22 (p<0.0001) and ∼40
kDa (p<0.0001) NFL fragments in hCAST mice, as compared to the wild-type controls.
Forty-eight hours after sciatic nerve transection, there was preservation of intact NFL
(p=0.0008) and reduction in the generation of both the ∼22 (p<0.0001) and ∼40 kDa
(p<0.0001) NFL fragments in hCAST mice, as compared to the wild-type controls.
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Effect of hCAST on morphological degeneration of CNS and PNS axonal
cytoskeleton
Next, we determined if calpain inhibition afforded cytoskeletal protection to
transected CNS and PNS axons. Five days after unilateral optic nerve transection,
animals were perfused for ultrastructural analysis of the nerves (Fig. 5). In uninjured
optic nerves, there were a total of 50,775±4345 and 54,912±2797 myelinated axons in
wild-type and hCAST mice, respectively (p=0.011; Fig. 6). After transection, there were
10,556±2229 axons remaining in wild-type mice (p<0.0001 compared to contralateral
uninjured side). There was a trend towards protection in hCAST mice (13919±3369
axons) compared to their wild-type littermates (p=0.03). For these 3 pairwise
comparisons a p<0.017 was considered significant. In both wild-type and hCAST mice,
most of the degenerating axons were diffusely filled with electron-dense material,
consistent with “dark” degeneration. A smaller population of transected axons underwent
GDC.
The peripheral nerves were examined 48 hours after unilateral sciatic nerve
transection. Myelinated sciatic nerve axons were scored for the presence or absence of
intact cytoskeleton. In uninjured nerves, essentially all axons (~99%) in wild-type and
hCAST animals had preserved cytoskeleton (p=0.84 comparing uninjured wild-type with
transgenic; Fig. 5 and 6). However, 48 hours after nerve transection in wild-type mice,
only 18.3±5.3% of the axons had cytoskeletal preservation (p<0.0001 compared to
uninjured wild-type). There was robust protection of transected axons in hCAST animals,
with 90.2±6.5% of axons having cytoskeletal preservation (p<0.0001 compared to
injured wild-type). In summary, there was robust morphological protection with specific
calpain inhibition in the PNS, and a trend towards protection in the CNS.
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Role of calpains in synaptic degeneration
Because of the biochemical and morphological protection of PNS axons with
calpain inhibition, we extended our investigation to the NMJ. The degeneration of the
presynaptic terminal is one of the earliest pathology seen after nerve transection (Griffin
et al., 1995). Eighteen hours after sciatic nerve transection, we removed the extensor
digitorum longus (EDL) muscle for immunostaining of the NMJs using a synaptic vesicle
marker (SV2; green) and TRITC-conjugated α-bungarotoxin (red; Fig. 7). SV2 and αbungarotoxin outline the presynaptic and postsynaptic terminals, respectively. In muscle
innervated by uninjured nerves of wild-type and hCAST mice, essentially all NMJs had
complete innervation, as defined by overlap of the SV2 and α-bungarotoxin labeling.
Eighteen hours after transection, 0.1±0.3% and 2.8±3.2% of the NMJs in wild-type and
hCAST mice, respectively, remained completely innervated (p=0.07). However,
11.8±7.9% of NMJs in wild-type mice had >50% but not complete innervation compared
to 71.3±10.3% of NMJs in the hCAST mice (p<0.001 versus wild-type injured) indicating
partial NMJ protection with hCAST overexpression.

Effect of calpains on synaptic dysfunction after PNS nerve transection
We have demonstrated biochemical and morphological protection of PNS axons,
as well as structural preservation of NMJs, after nerve transection in hCAST mice. We
next wanted to determine if hCAST also provided functional protection at the level of the
synapse. Sciatic nerves were studied 14 hours after transection. At this time point,
CMAP impairment likely represented synaptic dysfunction rather than failure of action
potential conduction (Miledi and Slater, 1970; Okamoto and Riker, 1969; Ribchester et
al., 1995). Fourteen hours after unilateral sciatic nerve transection, both nerves in the
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same animal were electrically stimulated, and compound muscle action potentials
(CMAP) were measured in the feet. There was no statistically significant difference in
CMAP amplitudes between the uninjured nerves in the wild-type (15.2±1.8 mV) and
hCAST mice (13.9±4.0 mV; p=0.54). Compared to the uninjured contralateral side, there
was a 35±32% decrement in CMAP amplitude in transected nerves in wild-type mice
(p=0.009). However, there was no statistically significant difference in CMAP amplitudes
between the injured nerves in the wild-type (9.9±5.0 mV) and hCAST mice (7.1±5.9 mV;
p=0.51).
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DISCUSSION
In summary, these findings strongly support the hypothesis that calpains cause
structural degeneration of transected PNS axons and their synapses. Calpain inhibition
was not sufficient to preserve NMJ function, however. There was robust biochemical
protection and a trend towards morphological protection after axon transection in the
CNS with overexpression of the calpain-specific inhibitor calpastatin. Calpain inhibition is
likely necessary, but not sufficient, to preserve axons and synapses, particularly in the
PNS. Therefore, intra-axonal calpain activity may be a necessary therapeutic target to
completely protect against axonal dysfunction and degeneration seen in many human
diseases, such as CNS and PNS trauma, cerebral ischemia, neurodegenerative
diseases, and peripheral neuropathies (Blumbergs et al., 1995; Glass, 2004; Medana
and Esiri, 2003; Povlishock and Becker, 1985; Shy et al., 2002; Smith and Meaney,
2000).

Causal role of calpains in Wallerian degeneration
Two in vivo studies examining the role of calpains in axonal degeneration
provided inconclusive results. Pretreatment with intraperitoneally administered calpain
inhibitor leupeptin, which was continued throughout the survival period, did not prevent
NFL degradation 72 hours post-sciatic nerve transection (Glass et al., 2002). However,
as leupeptin does not readily cross cell membranes, it is possible that there was not
sufficient intra-axonal concentration of leupeptin to inhibit calpains. In contrast, topical
application of the cathepsin and calpain inhibitor, Mu-F-HPh-FMK, directly to the optic
nerve crush site in opossums was slightly protective (Araújo Couto, et al., 2004). Ninetysix hours post-injury, there was statistically significant increase in axons with preserved
cytoskeleton (76±3.7% versus 67±4.2% nontreated injured) and reduction in
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degenerating axons in the drug treated group. As lysosomal cathepsins are important
components of the autophagy pathway (Uchiyama, 2001), which has been implicated in
axonal degeneration (Beirowski et al., 2010; Knöferle et al., 2010), the use of an inhibitor
of both calpains and cathepsins limits experimental interpretation.
Our study has several strengths, which allow us to conclusively determine that
intra-axonal calpain activity is casually related to axonal degeneration in vivo. First, we
identified and measured an axon-specific calpain reaction product (calpain-cleaved NFL)
in nerves to prove the presence of pathologic calpain activity in Wallerian degeneration.
Second, our strategy relied on overexpression of calpastatin, which only inhibits calpains
and no other proteases (Goll et al., 2003). Finally, immunohistochemistry of nerves
revealed calpastatin only in axons, limiting calpain inhibition to the axonal compartment.
We furthered our understanding of calpains in Wallerian degeneration by
examining the PNS synapse. CAST overexpression was able to reduce denervation of
NMJs in vivo 18 hours after nerve transection. However, it is not clear if it is localized
calpain activity within the NMJ presynaptic terminal that is directly responsible for
denervation, or that denervation is a “byproduct” of axonal degeneration. Nevertheless,
our data is consistent with and extends findings showing that pharmacologic calpain
inhibitors protects NMJ cytoskeletal structure in an ex vivo model of anti-ganglioside
antibody-mediated motor nerve terminal injury (O'Hanlon et al., 2003).

“Dark” degeneration in the CNS
Our observation that “dark” degeneration occurs in a large population of
transected CNS axons but not in the PNS is consistent with previous reports (Bignami et
al., 1981; George and Griffin, 1994; Marques et al., 2003; Narciso et al., 2001). The
molecular mechanism and functional significance of “dark” degeneration is not known.
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Spatially diffuse electron-dense material obscured visualization of cytoskeletal
components, so “dark” degenerating axons were not scored as intact. All together, this
data suggests that in hCAST mice, axons undergoing “dark” degeneration may have had
preserved cytoskeletal ultrastructure, and that the molecular mechanism underlying
“dark” degeneration and GDC are different.

Calpain inhibition is not sufficient for protection of synaptic function
We were unable to detect preservation of synaptic function measured at 14 hours
after sciatic nerve transection in hCAST mice. We quantified NMJs at 18 hours because
at this time point, there was sufficient denervation in wild-type mice to demonstrate an
injury effect. NMJ innervation was preserved in hCAST mice 18 hours after sciatic nerve
transection. In wild-type and hCAST mice, 11.8±7.9% and 71.3±10.3% of NMJs,
respectively, had >50% but not complete innervation after transection (p<0.001).
Potentially more informative is the observation that less than 3% of all NMJs in the
transected side of hCAST and wild-type mice were morphologically normal. Because of
the complexity involved in synaptic transmission, “slight” pathologic changes may render
the synapse nonfunctional or dysfunctional.
Calpain inhibition resulting in structural preservation without functional
improvement has been reported in other nerve injury models. Pharmacologic calpain
inhibitors protected against neurofilament and spectrin breakdown in optic nerves
exposed to ex vivo anoxia or oxygen-glucose deprivation, but there was no
electrophysiological preservation (Jiang and Stys, 2000; Stys and Jiang, 2002). In ex
vivo muscle preparations, the calpain inhibitor AK295 preserved immunoreactivity of the
Na+ channel Nav1.6, ankyrin G, Caspr, and neurofascin at the nodes, but did not afford
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protection of perineural currents or compound action potential in a model of anti-GD1a
antibody mediated injury (McGonigal et al., 2010).

Conclusions
Understanding the potentially shared mechanisms that cause axonal dysfunction
and degeneration may allow for common therapeutic targeting of axonal pathology in
diverse human diseases. In this report, we have demonstrated that calpains cause
axonal and synaptic degeneration during Wallerian degeneration. Preventing axonal
injury and degeneration will likely require ameliorating pathologic calpain activity in the
axon.
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Figure 2.1
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Fig. 2.1. Characterization of the hCAST transgenic mice. (A) Homogenates were
prepared from the cortex, optic nerves and sciatic nerves of hCAST transgenic mice
(TG) and wild-type (WT) littermates. Western blot was performed using antibodies
targeting calpastatin (CAST; sc-20779) or glyceraldehyde 3-phosphate dehydrogenase
(GAPDH). Other abbreviations: M, male; F, female. (B) Coronal sections of the cortex
and longitudinal and cross-sections (inset) of nerves were immunostained for neuronspecific class III ß-tubulin and either calpastatin (sc-20779) or human calpastatin
(hCAST; MAB 3084). Because brains were immersion-fixed, the focal intense green
CAST staining in the wild-type mice represents native IgG in the vasculature. Scale bar
= 25 µm. (C) Ex vivo analysis for functional hCAST in cortical homogenates from hCAST
transgenic mice compared to wild-type littermates. Proteolysis of the fluorogenic calpain
substrate Suc-Leu-Tyr-MNA results in increased fluorescent intensity. Fluorescent
measurements were performed every 3 min over ~30 min. Addition of wild-type cortical
homogenates (n=5) had no effect on exogenous calpain activity (5 nM), while addition of
hCAST cortical homogenates (n=5) completely blocked proteolysis of the fluorogenic
substrate. Error bars represent SD. *p<0.0001 compared to wild-type.
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Figure 2.2

Fig. 2.2. Calpain degrades neurofilament light (NFL) in vitro. Optic and sciatic nerves
were harvested from freshly sacrificed wild-type mice, sonicated on ice, and were
digested the same day without freezing. Reactions contained some combination of
calpastatin peptide (CAST), exogenous µ-calpain (µ-calp), exogenous m-calpain (mcalp), or CaCl2. Reactions were stopped at specified time points by addition of loading
buffer and heating to 95°C. Western blot was performed using an antiserum against
full-length recombinant mouse NFL (PRB-574C; 1:20000). Calpain proteolysis
resulted in loss of intact NFL, as well as generation of fragments with molecular
weights of ~55, ~40, and ~22 kDa.
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Figure 2.3

Fig. 2.3. Time course of NFL proteolysis after optic and sciatic nerve transection.
Wild-type mice underwent unilateral optic and sciatic nerve transection and were
sacrificed at the indicated times. The two left most lanes of each blot are controls in
which optic or sciatic nerves underwent in vitro calpain digest (see Fig. 2). The “-”
represent time 0 in the reaction that CaCl2 was omitted, while “+” was stopped 5
minutes after adding µ- or m-calpain and CaCl2. Western blot was performed using
an antiserum against full-length recombinant mouse NFL (PRB-574C; 1:20000). Both
optic and sciatic nerve transection resulted in NFL proteolysis, which generated
similar sized fragments (~40 and ~22 kDa) as seen with the in vitro calpain digest.
The latency period was longer after optic nerve transection. Other abbreviations: M,
male; F, female.
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Figure 2.4

Fig. 2.4. Effect of hCAST overexpression on NFL proteolysis 5 days after optic nerve
transection and 48 hours after sciatic nerve transection. (A) Western blot of homogenates
of transected nerves (cut) and the contralateral uninjured nerves from wild-type (WT) and
transgenic (TG) mice was performed using antiserum targeting NFL (PRB-574C; 1:20000).
(B) Quantification of intact NFL and the ~40 and ~22 kDa proteolytic fragments. n=6-9
mice per group. Human CAST blocks loss of full-length NFL, as well as the generation of
the ~40 and ~22 kDa fragments in both optic and sciatic nerves. *p<0.01 **p<0.001
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Figure 2.5
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Fig. 2.5. Effect of hCAST overexpression on cytoskeletal structure 5 days after optic
nerve transection and 48 hours and 5 days after sciatic nerve transection.
Representative light and electron microscopic images of wild type (WT) and hCAST
transgenic (TG) optic and sciatic nerves. An axon undergoing GDC is marked by single
arrow, while axons undergoing “dark” degeneration are marked by double arrow. Scale
bar=1 µm (EM), 10 µm (LM).

58

Figure 2.6

Fig. 2.6. Quantification of hCAST protection on cytoskeletal structure 5 days after
optic nerve transection and 48 hours after sciatic nerve transection. (A) For optic
nerves, quantification of intact myelinated axons in wild-type (WT) and transgenic
(TG) was performed. Total myelinated axon counts per nerve were reported for 5
days post-transected optic nerves and their contralateral uninjured controls. n=6-7
mice per group. (B) For sciatic nerves (7 WT and 4 TG mice), myelinated axons
were scored as intact or not, and the percentage intact was reported. Scoring was
performed on 48 hrs post-transected sciatic nerves and their contralateral
uninjured controls. There was statistically significant morphological protection of
sciatic, but not optic, nerves with hCAST overexpression. Each circle represents
an individual nerve, while horizontal bars represent means. *p<0.05 **p<0.0001
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Figure 2.7
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Fig. 2.7. Effect of hCAST overexpression on NMJ innervation 18 hours after sciatic
nerve transection. (A) Representative images of NMJs 18 hours after transection in wildtype and hCAST mice. SV2 (green) labels synaptic vesicles in the presynaptic
compartment, while α-bungarotoxin (red) labels acetylcholine receptors on the
postsynaptic membrane. NMJs in the uninjured contralateral side had consistently
complete innervation (not shown). (B) NMJ were classified into one of 4 groups on basis
of SV2 coverage of α-bungarotoxin labeling: (1) complete innervation, (2) ≥50%
innervation but not complete, (3) <50% innervation, but not absent, (4) innervation is
absent. The Y axis represents percent of NMJs in each group for an individual animal
(n=7-10 mice per group). ~100-150 NMJs were scored on the injured side. For each
animal, the percent from all 4 groups add up to 100%. Data from the uninjured side is
not shown. hCAST overexpression preserved NMJ innervation 18 hours after sciatic
nerve transection. *p<0.0001
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Figure 2.8

Fig. 2.8. Effect of hCAST overexpression on motor nerve responses of transected and
uninjured sciatic nerves. CMAPs were recorded from intrinsic foot muscles after
supramaximal stimulation of the sciatic nerve immediately distal to the transection site.
(A) Representative motor nerve responses from stimulation of wild type (WT) and
hCAST transgenic (TG) sciatic nerves 14 hours after transection and their uninjured
contralateral controls. Onset latency was measured from the initial negative deflection
from baseline as marked by the plus sign. Amplitude was measured from baseline to
peak as marked by the minus sign. (B) CMAP amplitudes are plotted for 10 WT and 9
TG mice. Each circle represents an individual nerve, while horizontal bars represent
means. *p<0.01
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Immediate short-duration hypothermia provides
long-term protection in an in vivo model of
traumatic axonal injury
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ABSTRACT
A prospective, multicenter, randomized trial did not demonstrate improved
outcomes in severe traumatic brain injured patients treated with mild hypothermia
(Clifton, et al., 2001). However, the mean time to target temperature was over 8 hours
and patient inclusion was based on Glasgow Coma Scale score so brain pathology was
likely diverse. There remains significant interest in the benefits of hypothermia after
traumatic brain injury (TBI) and, in particular, traumatic axonal injury (TAI), which is
believed to significantly contribute to morbidity and mortality of TBI patients. The longterm beneficial effect of mild hypothermia on TAI has not been established. To address
this issue, we developed an in vivo rat optic nerve stretch model of TAI. Adult male
Sprague-Dawley rats underwent unilateral optic nerve stretch at 6, 7 or 8 mm piston
displacement. The increased number of axonal swellings and bulbs immunopositive for
non-phosphorylated neurofilament (SMI-32) seen four days after injury was statistically
significant after 8 mm displacement. Ultrastructural analysis 2 weeks after 8 mm
displacement revealed a 45.0% decrease (p<0.0001) in myelinated axonal density in the
optic nerve core. There was loss of axons regardless of axon size. Immediate post-injury
hypothermia (32°C) for 3 hours reduced axonal degeneration in the core (p=0.027).
There was no differential protection based on axon size. These results support further
clinical investigation of temporally optimized therapeutic hypothermia after traumatic
brain injury.

KEYWORDS
diffuse axonal injury; trauma; optic nerve; brain injury; hypothermia
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INTRODUCTION
Currently, there are up to 6.5 million people in the United States living with the
devastating physical, cognitive, and economic costs of traumatic brain injury (TBI) (NIH
Consensus Development Panel on Rehabilitation of Persons with Traumatic Brain injury,
1999). An estimated 1.5 to 2 million cases of TBI occur each year in the US. It is
predicted by the year 2020, TBI will be the third leading cause of death and disability
each year in the world (Murray and Lopez, 1997). Traumatic axonal injury (TAI)
contributes to the high rate of morbidity and mortality seen in severe TBI patients without
space occupying lesions (Gennarelli, et al., 1982; Büki, et al., 2000). TAI is also believed
to contribute to neurologic dysfunction after mild TBI.
Studying TAI in the brain in vivo is complex as the traumatic event may
proximately damage nuclei, dendritic fields, nerve tracts, and vasculature. The interplay
between the various brain structures does not allow the investigator to isolate the
specific mechanism and consequences of TAI. Direct injury to neuronal cell bodies and
their dendritic fields, or glial cells and vasculature could have secondary effects on
axons. Hemorrhage, elevated intracranial pressure and secondary ischemia are
common after severe TBI, and are associated with poorer outcome. The difficulty in
identifying specific neuronal cell bodies, which give rise to the axons of interest, limits
experimental manipulation and interpretation. These limitations can be overcome in the
optic nerve stretch model. The optic nerve shares similar properties with white matter
tracts within the brain, including poor regenerative capacity, myelin sheath structure, and
the presence of oligodendrocytes (Hirano and Lena, 1995; Cho, et al., 2005).
In both humans and animals, trauma produces a rapid elongation of axons that
generally does not cause primary axotomy (immediate tearing of the axon) but leads to
progressive structural damage culminating in secondary axotomy (Jafari, et al., 1997;
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Maxwell and Graham, 1997; Povlishock, et al., 1997; Saatman, et al., 2003; Povlishock
and Katz, 2005). The distinction between primary and secondary axotomy is critical as
primary axotomy in the CNS is considered irreversible. Impairment of axonal transport
with subsequent accumulation of transported proteins and organelles, visualized using
antibodies targeting amyloid precursor protein (APP) or neurofilament, are hallmarks of
TAI. These sites of accumulated transported materials are known as axonal swellings.
Eventually, a constriction may form near the swelling that progresses to axonal
disconnection. This terminal increase in axonal diameter found after axonal
disconnection is termed axonal bulb.
Posttraumatic hypothermia has previously been shown to afford short-term
axonal protection in models of TAI. Hypothermia (32.0-32.5°C) induced immediately and
maintained for 4 hours after guinea pig optic nerve stretch reduced the number of β-APP
labeled axons in animals sacrificed 4 and 8 hours after injury (Maxwell, et al., 1999;
Maxwell, et al., 2005). Both studies also demonstrated preservation of cytoskeletal
ultrastructure with hypothermia. Twenty-four hours after impact acceleration head injury
in rats, there was a reduction in the number of APP-labeled axons with 1 hour of
hypothermia (32°C) induced immediately after injury (Koizumi and Povlishock, 1998).
Collectively, these past studies demonstrate the promise of using immediate mild
hypothermia in mitigating TAI. However, the long-term benefits of hypothermia remain
relatively unexplored. The previous studies counted APP-labeled axons, but this may
significantly underestimate the overall magnitude of the axonal damage caused by
trauma (Povlishock and Katz, 2005). It is not known whether all APP-labeled axons
ultimately degenerate.
To address this issue, we developed a rat model of in vivo optic nerve stretch
and demonstrated pathology similar to that observed in human TBI. Furthermore, we
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report for the first time sustained axonal preservation with immediate short-duration
hypothermia after isolated axonal stretch injury in vivo.
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MATERIALS AND METHODS
All animal procedures were performed in accordance with NIH guidelines for the
care and use of laboratory animals and were approved by our Institutional Animal Care
and Use Committee.

Surgical Preparation for Optic Nerve Stretch
Adult male Sprague-Dawley rats (weight 300-400 grams) underwent general
anesthesia with 2.5% isoflurane and were placed on a heating pad for surgery.
Anesthesia was maintained via a nose cone. The cornea was anesthetized with 0.5%
proparacaine, and the eye was kept moist at all times using sterile saline. The
conjunctiva was separated from the sclera using an incision extending around the entire
circumference of the eye except for the medial aspect (to minimize bleeding). A flexible
thin ring-shaped plastic sling, which had a continuous loop of 4-0 monofilament nylon
suture secured to it at two places 180° apart, was placed behind the eye. The sling had
a break in its ring so the ends could be spread apart to allow placement behind the eye,
and, after placement, the two ends of the ring were sutured together. The monofilament
nylon loop was then attached to the optic nerve stretch device.

Rat Optic Nerve Stretch
To receive optic nerve injury, rats were placed in a stereotactic head holder that
was positioned on the injury device (modified from Gennarelli, et al., 1989). We used
rats, rather than mice, for these experiments because of the larger anatomic dimensions
of the optic nerve, which allows for more precise control of the biomechanics of injury.
For experiments characterizing SMI-32 immunohistochemistry, rectal temperature was
used. For all other experiments, a probe placed in the temporalis muscle was used as a
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surrogate for brain temperature and was maintained at 37.0–37.5°C at the time of injury.
The head was positioned on the injury device such that the trajectory of the retro-orbital
portion of the optic nerve was aligned with the stroke of the solenoid. The sling was
connected to a force transducer (ELF T5000-a; Entran, Fairfield, NJ) mounted in series
with a solenoid (Lucas-Ledex, Vandalia, OH) and in parallel with a displacement
transducer (Trans-Tek Inc., Ellington, CT). To ensure consistent loading, a 30 g preload,
measured by the force transducer, was placed on the nerve. The magnitude of the
displacement was controlled by a micromanipulator that adjusts the distance traveled by
the solenoid piston. Preliminary experiments in freshly sacrificed animals (part of the
forebrain was removed so that the optic nerve was visualized during stretch) suggested
that the distance the piston traveled was significantly more than the actual stretch of the
optic nerve, consistent with past experiments in the guinea pig (Bain and Meaney,
2000). The magnitude of optic nerve stretch reported here refers to piston displacement.
Immediately after obtaining the preload, the solenoid was triggered to produce a rapid
elongation of the nerve. For 8 mm piston displacement, the nerve was extended to the
maximum displacement, held briefly, and then returned to its original pre-injury position
within 75 milliseconds of initially activating the solenoid. For the experiments in this
report, the peak displacement occurred 25 milliseconds after triggering the solenoid,
which is consistent with the timing of peak deformation that occurs within the brain
during conditions that cause diffuse axonal injury (Meaney, et al., 1995). The plateau
force, which was measured when the optic nerve was elongated to its maximum length,
ranged from approximately 220 to 360 grams after accounting for the initial preload.
Animals were excluded if injury to the globe or tearing of the optic nerve was
apparent by visual inspection. In a subset of animals without obvious injury to the globe
or optic nerve, pupils were dilated with 1% tropicamide for indirect fundoscopic
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evaluation, which revealed normal retinal vessels without retinal hemorrhage, and rarely
minimal intravitreal bleeding.
The contralateral uninjured eye was used as a control. Sham surgery was
performed on both optic nerves of two animals exactly as described except the solenoid
was not triggered. All animals were recovered on a heating pad until the animal
awakened from anesthesia, which usually took less than 5 minutes.

Hypothermia
All animals were subjected to unilateral 8 mm optic nerve stretch at
normothermia (temporalis temperature between 37.0 and 37.5°C). The contralateral
optic nerves in each animal served as controls. In the experimental group, hypothermia
was induced immediately after stretch by fan, cold water spray and ice packs, and the
animal was maintained at 32°C for 3 hours. Animals were then slowly rewarmed 1°C
every 40 minutes to a temperature of 37°C before ending general anesthesia. The
rewarming rate was selected based on a study by Maxwell, et al. (2005). Control animals
were maintained at 37.5°C and kept anesthetized (1-1.5% isoflurane by a nose cone) for
the same duration as the hypothermic animals.

Bright Field Microscopy
Tissue processing
Four days after optic nerve stretch, rats, under deep isoflurane anesthesia, were
perfused transcardially with cold 1x PBS followed by cold 4% paraformaldehyde in 0.1 M
phosphate buffer. The optic nerves and eyes were exposed by dissection and separately
removed from the head. Nerves were postfixed overnight before cryoprotection in 30%
sucrose.
71

Immunohistochemistry of optic nerves for conventional bright field microscopy
Optic nerves were cut longitudinally into 10 µm thick sections on a freezing
sliding microtome. Nerve sections were mounted on microscope slides and allowed to
dry over several days. Slides were rinsed in an ethanol series, pretreated in 5% H 2O2
and 83% methanol for 30 minutes at room temperature, and rinsed in 1x PBS. Sections
were blocked in 3% goat serum and 0.1% triton x-100. The tissue sections were
incubated overnight at 4oC with SMI-32 (1:2000; Sternberger Monoclonals Inc.,
Lutherville, MD, USA), which reacts with a non-phosphorylated epitope in neurofilament
H. Accumulation of neurofilament highlights axonal swellings and bulbs. Mounted
sections were then incubated with biotinylated goat anti-mouse secondary antibody
(1:600) for 1 hour at room temperature. The enzymatic reaction was visualized using 3,
3’ diaminobenzidine tetrahydrochloride. Slides were rinsed in xylene and coverslipped
with DPX.

Electron Microscopy
Tissue processing
Fourteen days after optic nerve stretch, rats, under deep isoflurane anesthesia,
were perfused transcardially with 1x PBS followed by 2% paraformaldehyde and 2%
glutaraldehyde in 0.1 M sodium cacodylate. Solutions were at room temperature. The
brain was removed and the optic nerves were left in situ and postfixed overnight at 4oC.
The optic nerves were then dissected from the skull, and allowed to remain in postfix
until ready for processing. Nerves were ossicated, dehydrated in ethanol and propylene
oxide. The prechiasmatic region of the optic nerve was embedded in epoxy resin and
oriented specifically for cross-sections of the axons. Eighty nm thick sections were

72

stained with uranyl acetate and bismuth subnitrite for ultrastructural analysis. One
section from each nerve was analyzed for quantification of myelinated axons.

Assessment of Histological Outcomes
Axonal accumulation of non-phosphorylated neurofilament (SMI-32)
Every eighth longitudinal section of the optic nerve (10 µm thick) was mounted on
slides and dried for several days. The sections were labeled for SMI-32 as described
above. Using a Leica DM4500B, 100x images of each section was captured by CCD
camera. The number of discrete swellings and bulbs (diameter larger than 2.5 microns)
in each mounted longitudinal section (starting from behind the eye to the optic chiasm) at
a final magnification of 200x was counted by two independent blinded observers (except
for sham injured nerves which were scored by one observer) (Figure 1). The total
number of swellings and bulbs per each optic nerve was determined by each observer.
The area of each mounted longitudinal section was calculated using NIH ImageJ and
summed to get the total area scored. The number of swellings and bulbs per square mm
was calculated for each optic nerve. Reported values for each nerve are the mean of two
observers.
Quantification of Myelinated Axons
Optic nerve sections prepared for transmission electron microscopy were imaged
using a JEOL JEM 1010 electron microscope aided by AMT HR-12 software and
Hamamatsu CCD camera. An outline of the optic nerve cross-section was made and the
x,y coordinates for the most superior and leftward points of the nerve border was
recorded. The starting point for image capture was determined using the x from the most
leftward coordinate and y from the most superior coordinate (Figure 2). Images were
taken every 70 microns across until the rightward edge of the optic nerve was reached.
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The camera was then moved 70 microns down, and images every 70 microns across the
optic nerve were taken. This process was repeated until the entire optic nerve was
systematically sampled (about 2% of the total area).
A counting frame was then overlay on each image (final magnification of
13,900x), and a blinded observer counted the number of myelinated axons that had
some preservation of ultrastructure. We did not count unmyelinated axons as they
comprise less than 1% of total axons in the rat optic nerve (Sugimoto et al., 1984). The
area of the optic nerve was calculated using NIH imageJ, and axon counts were
extrapolated so that total axons per optic nerve are reported.
Each image had known x, y coordinates. The coordinates of all images from
each optic nerve were plotted, and an ellipse was statistically fitted to the plot of the
image coordinates. An ellipse can be described by the length of its major and minor
axes. The length of the axes of the ellipse that result from the fit to the coordinate data
represents the standard deviation of the data in the coordinate plane where the origin of
the plane and the geometric center of the ellipse are coincident, and the major and minor
axes are colinear with the axes of the coordinate system. To determine the scaled
distance (i.e. percent) from the geometric center, an affine transform was performed and
the coordinate system was scaled so that the ellipse becomes a circle (Figure 3). An
affine transformation was performed in order to compensate for the varying aspect ratios
(length of minor axis:length of major axis) of optic nerve cross-sections. In addition, it
compensated for the different spatial orientation (location of centroid and rotation) of
nerve cross-sections by statistically fitting the ellipse. The distance from the geometric
center in the scaled coordinate system was used to rank the images. Images nearest to
the center were considered be taken from the nerve center, while the rest of images
were considered to be taken from the nerve periphery. Images were evenly divided
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between center and periphery. When there were an odd number of images for a nerve,
the additional image was classified as central. Axon densities are reported.
C. Axon cross-sectional area
A counting frame was overlay on each image taken from the central region of
each optic nerve (final magnification of 13,900x). Using Adobe Photoshop® CS3
Extended (v 10.0.1), a blinded observer used the quick selection tool to outline the
axoplasmic area of each myelinated axon. The cross-sectional areas of approximately
220-300 axons in the uninjured nerves and 40-280 in injured nerves were calculated.
The axons in each uninjured normothermic optic nerve were divided into quartiles based
on cross-sectional area. Using only the normothermic uninjured nerves, the mean 25th,
50th, and 75th percentiles were established, and these values were subsequently used to
separate the axons from the 24 optic nerves into four quartiles. The mean density of
axons (6 optic nerves in each group) in each quartile is reported. The first quartile
represent the smallest axons, while the fourth quartile represent the largest axons.

Statistical Analysis
The percentage axonal loss (the percent difference in axon number between the
injured and its contralateral control optic nerve) between the normothermic and
hypothermic groups was compared using a Student’s t-test. All other analyses were
performed using analysis of variance (ANOVA) in repeated measures. A p-value <0.05
for main effects and <0.2 for the interaction term was considered statistically significant.
Post-hoc pairwise comparisons were accomplished using the t-test with pooling of the
variance. Significance levels for post-hoc comparisons were adjusted for by using the
Bonferroni correction. These levels varied depending on the number of preplanned
pairwise comparisons made. Data are presented as means and standard deviation. All
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analyses were performed using SAS statistical software (Version 9.1, SAS Institute,
Cary NC).
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RESULTS
Immunohistochemical analysis of axonal injury
In our preliminary experiments, 10 mm of stretch consistently tore the optic
nerve. We therefore decided to compare number of axonal swellings and bulbs four days
after 6, 7 and 8 mm of stretch (SEVERITY, n=3 animals per group). Overall, there was a
significant INJURY effect (F=21.8, p=0.003) as well as an interaction
(INJURY*SEVERITY, F=2.3, p=0.186). Because we wanted to determine a level of
stretch severity that produced axonal injury, there were three pre-planned comparisons:
each injury severity with their respective contralateral control nerves. A p<0.016 was
considered significant. Axonal swellings and bulbs highlighted by SMI-32 labeling were
detected after all three injury severities with 8 mm stretch reaching statistical significance
relative to contralateral control nerves (p=0.009) (Figures 4 and 5). Injury was detected
throughout the nerve, but was mainly concentrated at the prechiasmatic segment. In a
separate experiment, the mean number (±SD).of swellings and bulbs per square mm 4
days after sham surgery were 1.04±1.07.
Hypothermia as a strategy for axonal protection after trauma
Overall axonal loss
Twelve rats (n=6 in both normothermia and hypothermic groups) were subjected
to unilateral 8 mm optic nerve stretch at normothermia. Right optic nerves served as
uninjured controls. In the TREATMENT group, hypothermia was immediately induced
after stretch. Target temperature of 32°C was reached at a mean (±SD) time of 16.4±1.8
minutes. An interim target of 34°C was reached at 10.8±2.0 minutes.
Fourteen days after injury, rats were euthanized by perfusion fixation and optic
nerve cross sections were prepared for transmission electron microscopy. There was a
significant INJURY effect (F=20.4, p=0.001) and an interaction (INJURY*TREATMENT,
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F=1.90, p=0.198). There were three pre-planned comparisons: injured versus control
nerves in normothermic animals, injured versus control nerves in hypothermic animals,
and normothermic injured versus hypothermic injured nerves. A p<0.016 was considered
significant. The number of myelinated axons was 89214±3348 and 86485±4286 in
normothermic and hypothermic control nerves, respectively. In injured optic nerves, the
number of myelinated axons was 56220±19090 (37.1% decrease, p=0.002) in the
normothermic group and 68922±20879 (20.4% decrease, p=0.051) in the hypothermic
group (Figures 6 and 7A). The mean number of axons in hypothermic and normothermic
injured nerves was not statistically different (p=0.14). Likewise, the overall percentage
axonal loss after injury (pairing each injured optic nerve to its contralateral uninjured
optic nerve) between the normothermic and hypothermic groups was not statistically
different (p=0.14) (Figure 7B).
Regionalization of stretch injury
Based on our histologic observations, stretch injury appeared to cause axonal
degeneration disproportionately in the central region of the nerve, leaving the periphery
relatively preserved. Among normothermic animals, there was an INJURY effect
(F=10.8, p=0.008) and an interaction (INJURY*REGION, F=10.5, p=0.01). There were
two pre-planned comparisons, and p<0.025 was considered significant. We found, in
normothermic animals, a statistically significant decrease in axonal density in the central
region (45.0%, p<0.0001), but not periphery (16.6%, p=0.049) after 8 mm optic nerve
stretch (Figure 8). We therefore decided to determine if immediate short-duration
hypothermia was axonal protective in the optic nerve core after stretch. Comparing core
axonal density between the normothermic and hypothermic injured nerves, only an
interaction effect was noted (TREATMENT*REGION, F=3.64, p=0.086). There was one
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pre-planned comparison, and p<0.05 was considered significant. Hypothermia protected
against axonal loss in the optic nerve core 2 weeks after optic nerve stretch (p=0.027).
Injury and hypothermic protection based on axon size
In normothermic rats, the mean percent decrease in axon density after optic
nerve stretch was 38.5%, 37.2%, 37.7%, and 63.2% in the first, second, third and fourth
quartiles, respectively (Figure 9). There was an INJURY effect (F=10.20, p=0.024) but
not a QUARTILE effect (F=1.80, p=0.190) or an interaction (INJURY*QUARTILE,
F=1.04, p=0.401). Stretch injury resulted in loss of axons regardless of axon size.
Comparing hypothermic to normothermic animals, there was an interaction
(INJURY*TREATMENT) effect for quartiles 2 (F=2.85, p=0.122) and 4 (F=3.40, p=0.095)
but not for quartiles 1 (F=1.68, p=0.212) or 3 (F=0.00, p=0.991). However, post-hoc
comparisons did not reveal any statistically significant difference between normothermic
versus hypothermic injured nerves. Despite an overall treatment effect in the optic nerve
core with hypothermia, there was no statistical difference between normothermic versus
hypothermic injured nerves in any of the four quartiles.
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DISCUSSION
Rat optic nerve stretch is a potentially powerful model to study the mechanism of
TAI that occurs in human TBI. Our model replicates histopathologic outcomes, including
SMI-32-labeled swellings and bulbs and axonal loss, seen in human TBI, and may
possibly be used to study mild and severe TAI. Using this model, we were able to
demonstrate robust regional long-term axonal protection with short-duration hypothermia
initiated immediately after injury. The purpose of this investigation was primarily
mechanistic. Our goals were to demonstrate that an intervention performed after trauma
can provide long-term axonal protection, and that secondary axotomy is preventable.
Defining the therapeutic window for post-injury hypothermia is a goal for future
investigations.

Our model replicates human pathology seen after TBI
The characteristics of axonal injury and degeneration seen after optic nerve
stretch mimic those found in established whole brain models of axonal injury, as well as
in human brain after TBI. Axonal swellings and bulbs are hallmarks of TAI. In the rodent
impact acceleration head injury model, APP, which undergoes anterograde transport like
neurofilament, immunoreactivity was seen in the corticospinal tract and medial
longitudinal fasciculus in injured rats (Büki, et al., 2003). Nonimpact rotational
acceleration in primates and pigs resulted in axonal swellings and bulbs diffusely in
white matter (Gennarelli, et al., 1982; Chen, et al., 1999).
The pathology seen in the optic nerve stretch model also recapitulates what is
seen in mild and severe TBI in humans. Using antibodies targeting neurofilament
(including SMI-32), Grady, et al. (1993) demonstrated the progression from axonal
swellings to bulbs in white matter in TBI patients. APP accumulations had been
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demonstrated within axons of the corpus callosum after severe TBI (McCracken, et al.,
1999). In addition, APP immunoreactive axonal swellings were described in the corpus
callosum, fornices, brainstem, and subcortical white matter in mild TBI patients who died
of other causes (Blumbergs, et al., 1994). Degeneration and atrophy of the fornices and
corpus callosum as measured using magnetic resonance imaging have also been
described (Levin, et al., 1990; Gale, et al., 1993).
There may be an injury dose response in our model. There was a mean of 82.6
swellings and bulbs per square mm after 8 mm optic nerve stretch, but only 22.0 after 6
mm stretch and 1.2 in control nerves. With 3 animals in each group, several of the posthoc comparisons were not statistically different. Increasing our sample size may allow us
to demonstrate statistically different injury dose responses. This may allow for the study
of therapeutic intervention after mild and severe TAI with our model.

Post-injury hypothermia provides long-term protection after TAI
Posttraumatic hypothermia had previously been shown to afford short-term
axonal protection in models of TAI (Koizumi and Povlishock, 1998; Maxwell, et al., 1999;
Maxwell, et al., 2005). The therapeutic benefit of hypothermia was demonstrated as late
as 8 hours after guinea pig optic nerve stretch (Maxwell, et al., 2005) and as late as 24
hours after rat impact head acceleration injury (Koizumi and Povlishock, 1998). Both
studies quantified APP-labeled axons but it is not known whether anterograde transport
disruption is reversible or whether all APP-labeled axons must degenerate. In one study,
Brodhun, et al. reported that early posttraumatic hypothermia was not axonal protective
in juvenile pigs subjected to fluid percussion injury and hypovolemic hypotension.
However, based on the graphical presentation of their data, the mean number of APPlabeled axons in the normothermic injured animals without elevated intracranial pressure
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(ICP) was more than double that of hypothermic animals (none experienced elevated
ICP). Therefore, this study may have lacked adequate power to detect a treatment
effect.
We are the first to determine that axonal protection seen with short-term
hypothermia is preserved long-term after accounting for the regionalization of injury after
optic nerve stretch. We were unable to detect a statistically significant difference in total
axonal counts 2 weeks post-stretch between normothermic animals and those treated
with short-duration hypothermia in spite of a mean 17% absolute reduction in axon loss
with hypothermia. We believe our inability to detect at a statistical difference was due to
the large intra-group variability in total axonal counts and the relative concentration of
injury in the optic nerve core. When regional density of myelinated axons was compared,
post-injury hypothermia reduced axonal loss in the nerve core.
It is unclear why the central region of the optic nerve is preferentially injured.
Maxwell, et al. (1999) had earlier reported that β-APP immunolabeling occurred
exclusively in the central 30% of the guinea pig optic nerve after stretch. Solid
mechanics dictates that homogenous, isotropic materials have a uniform stress
distribution under axial loading. However, the optic nerve is neither isotropic nor
homogenous. Past work showed that the microstructure of the optic nerve leads to
nonlinear behavior of the structure as it is gradually elongated (Bain, et al., 2003;
Meaney, 2003). One key parameter in this nonlinear behavior is the gradual
straightening of the axons during slow extension, which leads to an increase in the
fraction of axons bearing mechanical load at higher elongations. One possible
mechanical reason for the differential injury pattern in our study is the change in axonal
microstructure between the periphery and the core. Future data on the regional changes

82

in the microstructure within the rat optic nerve would clarify if this were a contributing
factor for this observation.
It is not clear if TBI preferentially injures larger caliber axons as more recent
studies have suggested otherwise (Povlishock, 1992). However, different size axons
appear to respond differently to injury. In the guinea pig optic nerve stretch model, small
and large axons have different responses 4 hours after injury (Jafari, et al., 1997; Jafari,
et al., 1998). In small axons, there was an increase in neurofilament number and density
without detectable changes in microtubules, whereas larger axons experienced
microtubule loss with either no change or a loss of neurofilament (Jafari, et al., 1997).
Differential cytoskeletal alterations in different size axons were seen up to 7 days (final
time point) after guinea pig optic nerve stretch (Maxwell, et al., 2003). From our data,
optic nerve stretch in the rat resulted in loss of axons regardless of size. Despite an
overall treatment effect in the optic nerve core with hypothermia, there was no statistical
difference in the density of axons of different sizes between normothermic and
hypothermic injured nerves. This may again be due to limited statistical power. Our
cross-sectional axonal area measurements may have been overestimates as not all
axons were cut perfectly transversed. In spite of this, the data was robust and appeared
similar across all four quartiles (Figure 9).
The mechanism of axonal protection with short-duration immediate hypothermia
remains to be established. It has been previously demonstrated in animal models of TAI
that short-duration hypothermia reduced microtubule loss, prevented alteration in
neurofilament structure, and blunted early calpain activity (Büki, et al., 1999a; Maxwell,
et al., 1999; Sun, et al., 2002). The mechanism is likely multifactorial, and may also
include reduction in brain metabolic rate, blockade of excitotoxicity, calcium antagonism,
and modulation of the inflammatory response (Sahuquillo and Vilalta, 2007).
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Several studies have demonstrated benefit of mild hypothermia after severe TBI
in humans (Jiang, et al., 2006; Jiang and Yang, 2007). However, a prospective,
multicenter, randomized trial did not show improved outcomes in severe TBI patients
treated with mild hypothermia (Clifton, et al., 2001). In that study, the mean time to target
temperature was over 8 hours and patient inclusion was based on Glasgow Coma Scale
score so brain pathology was likely diverse. In animal models, axonal pathology was
seen within minutes of injury and hypothermia was usually instituted immediately
(Koizumi and Povlishock, 1998; Büki, et al., 1999a; Maxwell, et al., 1999; Sun, et al.,
2002). Severe TBI in humans often include axonal injury, as well as focal or more diffuse
hemorrhage, with ischemia and ICP elevations as secondary complications.
Hypothermia potentially can be modified to target specific pathology. For example,
hypothermia targeting refractory ICP elevation can be started hours after injury but must
be prolonged for optimal benefit (Jiang, et al., 2006). In our model, we demonstrated that
immediate, short-duration hypothermia provided long-term axonal protection.

Summary
In summary, optic nerve stretch in rats appears to model important phenomena
that occur after human TBI. Injury and degeneration of the rat optic nerve mimic the
histopathologic changes seen in CNS white matter tracts after human TBI. We were able
to demonstrate long-term axonal protection with immediate short-duration hypothermia
after TAI using this model.
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Figure 3.1

Figure 3.1. Scoring of SMI-32 labeled swellings and bulbs. (A) Ten µm thick section
of an optic nerve from an animal sacrificed 4 days after 8 mm optic nerve stretch.
(B) Discrete swellings and bulbs were counted if a circle with a diameter of 2.5 µm
were completely contained within their border. Lime green circles have a diameter of
2.5 µm. Scale bar = 50 µm.
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Figure 3.2

Figure 3.2. Systematic sampling of optic nerve cross-sections using an electron
microscope. Coordinates for the most superior (x2,y2) and leftward (x1,y1) points of
the nerve were established (black dots). The starting point for image capture (red
dot) was determined using the x1 from the most leftward point and y2 from the most
superior coordinate. Images were captured every 70 µm across and down from the
starting point. Disruption of normal architecture is apparent even in this low power
image of an optic nerve taken from an animal sacrificed 2 weeks after normothermic
8 mm optic nerve stretch. Scale bar = 100 µm.
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Figure 3.3

Figure 3.3. Affin transformation of coordinates of electron microscopy images taken from
an optic nerve. (A) Idealized ellipse overlay on spatial plot of coordinates. (B) Affine
transformation of original coordinates (open circles). Filled circles represent the scaled
coordinates.
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Figure 3.4

Figure 3.4. Traumatic axonal injury 4 days after optic nerve stretch. SMI-32
immunolabeling of non-phosphorylated neurofilament in 10 µm thick longitudinal
sections after 6, 7, and 8 mm optic nerve stretch compared to uninjured (control) optic
nerve. Images captured at 100x magnification. Scale bar = 50 µm.
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Figure 3.5

Figure 3.5. Number of swellings and bulbs per square mm in control and injured nerves.
Every 8th longitudinal section of the optic nerve (10 µm thick) was scored. Three nerves
in each injury group and the 9 contralateral nerves served as controls. Horizontal bars
represent means. *p=0.009 relative to their respective contralateral control optic nerves.
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Figure 3.6

Figure 3.6. Axonal degeneration 2 weeks after 8 mm optic nerve stretch. Representative
electron microscopy images taken from the central and peripheral regions of uninjured
and injured optic nerves. Images captured at 13,900x magnification. Scale bar = 1 µm.
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Figure 3.7

Figure 3.7. Overall effect of post-injury hypothermia on axonal degeneration. (A) Total
axonal counts from control and injured optic nerves from 6 normothermic and 6
hypothermic animals. *p=0.002 when comparing control and injured normothermic
groups. (B) Percent difference in total axonal counts between the injured optic nerve and
contralateral control nerve. Horizontal bars represent means.
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Figure 3.8

Figure 3.8. Regional effect of post-injury hypothermia on axonal degeneration. Axon
densities from control and injured optic nerves from 6 normothermic and 6
hypothermic animals. Error bars represent standard deviation. *p<0.0001 relative to
control normothermia core. **p=0.027 relative to injured normothermia core.
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Myelinated axons per 100 square microns

Figure 3.9
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Figure 3.9. Injury and hypothermic protection based on axon size. Axons with crosssectional areas less than 0.56, between 0.56 and 0.92, between 0.92 and 1.59, and
greater that 1.59 µm2 are grouped into the first, second, third and fourth quartiles,
respectively. Quartiles were based on the size distribution of axons in control
normothermic optic nerves. Error bars represent standard deviation. *p≤0.01 when
comparing control and injured normothermic animals.
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CHAPTER 4:
Short-duration treatment with the calpain inhibitor
MDL-28170 does not protect axonal transport in
an in vivo model of traumatic axonal injury
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ABSTRACT
Traumatic axonal injury is characterized by early cytoskeletal proteolysis and
disruption of axonal transport. Calpain inhibition has been shown to protect axons in
rodent models of traumatic brain injury. However, in these models, both white and gray
matter are injured making it difficult to determine if calpain inhibitors are directly
protecting injured axons. To address this issue, we used our rat optic nerve stretch
model to test the hypothesis that early calpain inhibition directly protects central nervous
system (CNS) axons following stretch injury. Rats were given an intravenous bolus of
the calpain inhibitor MDL-28170 (30 mg/kg) 30 minutes prior to unilateral optic nerve
stretch, followed by a 15 mg/kg/hr intravenous infusion over the next 2.5 hours.
Immunohistochemical analysis of optic nerves 30 minutes after stretch injury revealed
variable increases of calpain-cleaved α-spectrin that appeared less evident in stretched
nerves from drug treated rats, although this difference was not statistically significant.
Retrograde axonal transport measured by fluorogold labeling of retinal ganglion cells
was significantly impaired after stretch injury. However, there was no difference in the
number of fluorogold labeled cells in the vehicle vs. drug treatment groups. These
results suggest that early short-duration calpain inhibitor therapy with MDL-28170 is not
an effective strategy to prevent disruption of axonal transport following isolated axonal
stretch injury in the CNS.

KEYWORDS
axonal injury; axonal transport; traumatic brain injury; animal studies; adult brain injury
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INTRODUCTION
Worldwide, traumatic brain injury (TBI) leading to death or hospitalization is
estimated to afflict over 10 million people annually (Hyder et al., 2007). It is predicted by
the year 2020, road traffic injuries, which are currently the leading cause of TBI, will be
the third leading cause of death and disability (Murray and Lopez, 1997). Traumatic
axonal injury (TAI) is thought to be a major contributor to the neurologic dysfunction
seen after mild TBI, as well as the high morbidity and mortality seen in severe TBI
patients.
Implicated in TAI, calpains are a family of Ca2+-dependent nonlysosomal
proteases involved in cytoskeletal remodeling, cell-cycle regulation, signal transduction,
apoptosis, and necrosis (Zatz and Starling, 2005). There are two ubiquitous isoforms,
calpain I and calpain II, which differ in the Ca2+ concentration required for in vitro activity.
Early calpain activity after trauma is likely caused by reversible Ca2+ overload either due
to disruption of the axolemma or dysregulation of ionic transport proteins (Iwata et al.,
2004; Wolf et al., 2001). Directly measuring axonal Ca2+ immediately after TAI in vivo is
particularly challenging. However, isolated stretch of neurites of primary cortical neurons
resulted in an immediate rise in Ca2+ in injured processes (Iwata et al., 2004; Staal et al.,
2010). Calpain activity has been reported to be elevated within minutes after
experimental TAI (Büki et al., 1999b; Saatman et al., 2003). In a mouse optic nerve
stretch model, diffuse calpain activity measured by immunolabeling of calpain-cleaved αspectrin (Ab38) was detected 20-30 minutes post-injury (Saatman et al., 2003). This
signal was typically no longer detectable at 4 hours post-injury. Although a direct
measure of calpain activity and elevated cytosolic Ca2+, immunoreactivity for calpaincleaved α-spectrin also signals cytoskeletal proteolysis and degradation. In addition to αspectrin, the neurofilament triplet proteins, tubulin, and tau are known calpain substrates.
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In both humans and animals, trauma produces a rapid elongation or deformation
of axons that generally does not cause primary axotomy (immediate tearing of the axon)
but leads to progressive structural damage culminating in secondary axotomy (Jafari et
al., 1997; Maxwell and Graham, 1997; Povlishock and Katz, 2005; Povlishock et al.,
1997; Saatman et al., 2003). Impairment of axonal transport with subsequent
accumulation of transported proteins and organelles, commonly visualized using
antibodies targeting beta-amyloid precursor protein (ß-APP) or nonphosphorylated
neurofilament, are hallmarks of TAI. A more direct measure of transport, such as
retrograde transport of fluorogold after its injection into the superior colliculus, is
disrupted after optic nerve stretch (Saatman et al., 2003). It is believed that posttraumatic calpain activity within axons contributes to transport disruption, cytoskeletal
degradation, and subsequent axotomy. However, there is also robust calpain activity in
neuronal somata and dendrites after TBI (Saatman et al., 2010). Trying to measure the
role of axonal calpains in whole brain TBI models is complex because many supraaxonal structures are affected. In this study, we address this issue by using an in vivo
optic nerve stretch model, where injury is localized primarily to axons (Ma et al., 2009).
We have also demonstrated that this model is amenable to therapeutic intervention as
short-duration post-injury hypothermia reduced axonal degeneration 2 weeks after nerve
stretch.
Pharmacologic inhibition of CNS calpain activity in vivo remains challenging, and
no ideal agent has emerged. However, the cell-permeable MDL-28170 is one of the
most well studied calpain inhibitor, has high specificity, and ameliorated TAI in global
brain injury models. A single intravenous (IV) bolus (30 mg/kg) of MDL-28170 has been
shown to reduce axonal pathology in global head injury models (Ai et al., 2007; Büki et
al., 2003; Czeiter et al., 2009). It is not known whether pharmacologic protection occurs
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at the level of the axons, supra-axonal structures or both as the injury model is not
selective to axons. This may have important clinical implications as certain brain injuries
may have predominant axonal versus somal/dendritic effects. There are no published
studies evaluating any calpain inhibitor in the optic nerve stretch model.
The goal of this study was to determine if a calpain inhibitor strategy targeting
early pathologic calpain activity would prevent the disruption of axonal transport in a
model of isolated TAI. Using our established rat optic nerve stretch model, we tested a
pharmacologic strategy previously shown to protect axons in other models of TBI. We
hypothesized that early intravenous therapy with the calpain inhibitor MDL-28170 will
reduce α-spectrin proteolysis and axonal transport disruption after optic nerve stretch.
These results could have important implications for targeting pathologic calpain activity
after TBI.
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MATERIALS AND METHODS
All animal procedures were performed in accordance with NIH guidelines for the care
and use of laboratory animals and were approved by our Institutional Animal Care and
Use Committee.

Rat Optic Nerve Stretch
Adult male Long-Evans rats (weight 300-400 grams) underwent general
anesthesia with 2.5% isoflurane and were placed on a heating pad. Anesthesia was
maintained via a nose cone. A femoral venous catheter was placed by cut-down for drug
therapy. To receive optic nerve injury, rats were placed in a stereotactic head holder that
was positioned on the injury device (modified from Gennarelli et al., 1989). The cornea
was anesthetized with 0.5% proparacaine, and the eye was kept moist at all times using
sterile saline. The conjunctiva was separated from the sclera using an incision extending
around the entire circumference of the eye except for the medial aspect (to minimize
bleeding). A flexible thin ring-shaped plastic sling, which had a continuous loop of 4-0
monofilament nylon suture secured to it at 4 places 90° apart, was placed behind the
eye. The sling had a break in its ring so the ends could be spread apart to allow
placement behind the eye, and, after placement, the two ends of the ring were tied
together. The monofilament nylon loop was then attached to the optic nerve stretch
device.
The head was positioned on the injury device such that the trajectory of the retroorbital portion of the optic nerve was aligned with the stroke of the solenoid. The sling
was connected to a force transducer (LFS 270; Cooper Instruments & Systems,
Warrenton, VA) mounted in series with a solenoid (Lucas-Ledex, Vandalia, OH). To
ensure consistent loading, a 12 gram preload, measured by the force transducer, was
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placed on the nerve. The magnitude of the displacement was controlled by a
micromanipulator that adjusts the distance traveled by the solenoid piston. The 5.5 mm
magnitude of optic nerve stretch reported here refers to piston displacement. The
distance the piston traveled was significantly more than the actual stretch of the optic
nerve consistent with our past experiments in the guinea pig and rat (Bain and Meaney,
2000; Ma et al., 2009). Immediately after obtaining the preload, the solenoid was
triggered to produce a rapid elongation of the nerve. Force measurements were
captured at 10 kHz using LabVIEW SignalExpress (National Instruments, Austin, TX).
For 5.5 mm stretch, the nerve was extended to the maximum displacement, held briefly,
and then returned to its original pre-injury position within 75 ms of initially activating the
solenoid. The peak displacement occurred within 25 ms after triggering the solenoid,
which is consistent with the timing of peak deformation that occurs within the brain
during conditions that cause diffuse axonal injury (Meaney et al., 1995). Peak force
ranged from approximately 700-1000 grams. Animals were excluded if injury to the globe
or tearing of the optic nerve was apparent by visual inspection. Approximately 30% of
optic nerves tore. Twelve animals (6 in each group) were assessed for Ab38 labeling,
while another 12 (5 in the DMSO group and 7 in the MDL-28170 group) were scored for
fluorogold transport.
Rectal temperature was maintained at approximately 36.5–37.5°C at the time of
injury and then for 2 additional hours. Erythromycin ophthalmic ointment was applied to
both eyes in all animals, and the lids of the injured eye were sutured together for 2 days
in animals surviving for 4 days to prevent corneal drying. The contralateral uninjured eye
and optic nerve were used as controls. Animals sacrificed at 4 days received fluorogold
injections immediately after optic nerve stretch, while animals perfused 30 minutes after
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optic nerve stretch for Ab38 immunohistochemistry were kept anesthetized on a heating
pad until perfusion.

MDL-28170 therapy
Prior to injury, a 30 mg/kg bolus of MDL-28170 (50 mg/ml DMSO; Enzo,
Plymouth Meeting, PA) or equal volume of DMSO vehicle was injected over 10-15
minutes. Immediately after completion of the bolus, infusion of 15 mg/kg/hr MDL-28170
or equivalent volume of vehicle was initiated and continued for 2.5 hours. To achieve
maximum calpain inhibition at time of injury, optic nerve stretch was performed 30
minutes after completion of the initial IV bolus (Markgraf et al., 1998; Thompson et al.,
2010).

Injection of fluorogold into the superior colliculus
To label retinal ganglion cells (RGCs) that were capable of retrograde transport
after stretch injury, animals received bilateral injections of fluorogold (Fluorochrome,
Denver, CO) into each superior colliculus. Immediately after optic nerve stretch, a
midline scalp incision was made and the skull exposed by blunt dissection. Burr holes
were drilled over each superior colliculus (6.8 mm posterior to bregma, 1.5 mm lateral to
the sagittal suture). A total of 3 µl of 5% fluorogold was injected over 7.5 minutes at two
depths (3.5 and 4.3 mm). The scalp was then sutured, and animals were given 0.05
mg/kg intraperitoneal (IP) buprenorphine prior to recovering.

Immunohistochemistry for calpain cleaved α-spectrin in optic nerves
Thirty minutes after optic nerve stretch, rats were transcardially perfusion fixed
with cold 1x PBS followed by cold 4% paraformaldehyde in 0.1 M phosphate buffer. The
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optic nerves were exposed by dissection, removed from the head and postfixed for 2-3
hours in 4% paraformaldehyde (4°C). Nerves were subsequently cryoprotected in 30%
sucrose. The distal 4 mm of both the right and left optic nerves of the same animal were
frozen in the same OCT block, and were cut longitudinally into 10 µm thick sections on a
cryostat. Every 10th longitudinal section of the right and left optic nerve in the same
animal was mounted on the same slide. After drying, slides were pretreated in 0.5%
H2O2 and 30% methanol for 15 minutes at room temp, rinsed in 1x PBS, and blocked in
3% goat serum and 0.1% triton x-100. The tissue sections were incubated overnight at
4oC with Ab38 (1:20,000, kind gift from R. Siman, University of Pennsylvania), which
reacts with calpain-cleaved α-spectrin. After further PBS rinses, the slides were
incubated with biotinylated goat anti-rabbit secondary antibody (1:1000; Vector Labs,
Burlingame, Ca) for 1 hour at room temp. The enzymatic reaction was visualized using
3, 3’ diaminobenzidine tetrahydrochloride. Slides were rinsed in xylene and coverslipped
with DPX.
For semiquantitative assessment of axonal Ab38 labeling, 200x images of the
region with the most intense Ab38 labeling in every 10th longitudinal section were
captured by CCD camera attached to a Leica DM4500B (Buffalo Grove, IL). Camera and
microscope settings were kept constant. The region of greatest Ab38 labeling was
almost invariably 1 to 2 mm from the chiasm, which is consistent with a study by
Saatman et al. (2003). The scorer, who was blinded to both treatment and injury, used
Adobe Photoshop to convert images to grayscale, followed by applying the invert filter so
more Ab38 staining translated to higher intensity. NIH ImageJ was then used to measure
the integrated density along a line drawn perpendicular to the long axis of the nerve and
across the region with the most intense Ab38 labeling. The sum of the integrated density
from every 10th longitudinal section was divided by the sum of the lengths of the drawn
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line (width of the nerve sections). The mean value obtained from the uninjured nerve
was subtracted from the injured side of the same animal. The higher the number, the
more intense the staining in the injured nerve versus the contralateral uninjured nerve.

Assessment of fluorogold axonal transport in retinal ganglion cells
Four days after optic nerve stretch, a rats in each group were reanesthetized and
transcardially perfusion fixed as described above. Retinas were removed from the eye
and postfixed for 2-3 hours in 4% paraformaldehyde (4°C). After washing with 1x PBS,
retinal flat mounts were blocked in 10% goat serum, 1% BSA, and 0.2% triton x-100 in
1x PBS for one hr at room temp. Retinas were incubated overnight at 4oC with TUJ1
(1:1000; Covance, Princeton, NJ), which labels RGCs. After further washes, retinas
were incubated in alexa 488 goat anti-mouse (1:1000; Molecular Probes, Eugene, OR)
overnight at 4oC. Retinas were washed and coverslipped with fluoromount.
After TUJ1 immunohistochemistry, the retina was flat mounted and viewed with a
fluorescent microscope (Leica DM4500B). Fluorogold was imaged using the A4 filter
cube. Images of labeled RGCs were taken in black and white (and subsequently
colorized) at 200x mag in 12 standard fields—1/6, 3/6 and 5/6 of the retinal radius from
the center of the retina in each quadrant. FG-positive RGCs were counted by a blinded
observer using Adobe Photoshop and NIH ImageJ.

Statistical Analysis
The Ab38 signal intensities in the DMSO and MDL-28170 groups were compared
using the Student’s t-test. To compare fluorogold counts, analysis of variance in
repeated measures was performed. A p-value < 0.05 for main effects and <0.2 for the
interaction space were considered statistically significant. Pairwise comparisons were
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specified a priori and were accomplished using the t-test with pooling of the variance.
Significance levels for pairwise comparisons were adjusted for by using the Bonferroni
correction. There were two pre-planned comparisons: injured versus uninjured retinas in
DMSO-treated animals, and DMSO versus MDL-28170 injured retinas. For these 2
pairwise comparisons, a p<0.025 was considered significant. Data are presented as
means and standard deviations. All data were analyzed using SAS statistical software
(version 9.2, SAS Institute, Cary, NC).
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RESULTS
Effect of MDL-28170 administration on calpain-mediated α-spectrin degradation
Thirty minutes after optic nerve stretch, the most intense Ab38 labeling was seen
1-2 mm from the optic chiasm (Fig. 1). In this region of intense signal, it was difficult to
identify individual Ab38 labeled axons, whose diameters are approximately 1 µm, in a 10
µm thick section. Ab38 signal was not seen in the contralateral unstretched nerve.
Based on semiquantitative analysis, injured nerves from animals treated with
DMSO have variable amounts of Ab38 labeling 30 minutes after injury relative to
contralateral uninjured controls (intensity difference = 7.6±10.7). In contrast, Ab38
labeling in injured nerves from MDL-28170 treated rats was similar to the contralateral
nerve in all cases (intensity difference = -0.2±2.2). However the mean intensity of
staining was not statistically different between treatment groups (p=0.11).

Fluorogold positive cells in the retina
As a functional outcome, we wanted to determine if the disruption of retrograde
transport after optic nerve stretch could be ameliorated with calpain inhibition. Transport
of fluorogold injected into the superior colliculus has been previously reported to be
impaired after optic nerve stretch in mice (Saatman et al., 2003). In our model, there was
a significant INJURY effect (p<0.0001) but not a TREATMENT effect (MDL-28170
versus DMSO, p=0.74) nor interaction (INJURY*TREATMENT, p=0.87). We detected a
significant decrease in the number of fluorogold labeled RGCs after optic nerve stretch
in animals administered DMSO, indicating disruption of retrograde axonal transport
(p=0.002; Fig. 2). However, preinjury short-duration MDL-28170 therapy was not
protective relative to DMSO injured retinas (p=0.93). The percentage decrease in FG
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labeled RGCs after optic nerve stretch (comparing injured to its contralateral uninjured
nerve) was 66±30% in DMSO treated rats versus 64±25% in MDL-28170 treated rats.
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DISCUSSION
Overall, we were unable to demonstrate statistically significant inhibition of early
post-injury calpain activity or long-term protection of axonal transport with intravenous
MDL-28170 pretreatment in our rat optic nerve stretch injury model. Unlike the effects
demonstrated in other models of traumatic brain injury, our results suggest that early
calpain inhibitor therapy with MDL-28170 might have limited potential in directly
preventing disruption of axonal transport caused by isolated axonal stretch injury.

Calpain inhibition in TBI
Intravenous MDL-28170 has been demonstrated to penetrate into the
parenchyma of uninjured brains as well as having neuroprotective properties after
ischemic and traumatic brain injury (Markgraf et al., 1998; Thompson et al., 2010). The
blood-optic nerve barrier is similar in structure to the blood-brain barrier (Zhao et al.,
2007). A single 30 mg/kg IV dose of MDL-28170 30 minutes prior to impact head
acceleration injury in rats reduced ß-APP and RMO-14 staining in the corticospinal tract
and medial longitudinal fasciculus 2 hours post-injury (Büki et al., 2003). RMO-14 is
believed to indicate pathologic proteolysis or dephosphorylation of neurofilament
sidearms. Czeiter et al. (2009) subsequently used the same dosing strategy, which
resulted in improved axolemmal integrity in the corticospinal tract 2 hours post-impact
head acceleration injury. Longer-term protection was also achieved with a single 30
mg/kg IV dose of MDL-28170. Given 30 minutes prior to fluid percussion injury in rats,
there was preservation of compound action potential and decreased ß-APP labeling of
corpus callosum up to 7 days after injury (Ai et al., 2007).
Trying to tease apart the role of axonal calpains in in vivo whole brain TBI models
is complex as the traumatic event may proximately damage nuclei, dendritic fields, nerve
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tracts, glia, and vasculature (Ma et al., 2009). The interplay between the various brain
structures does not allow the investigator to isolate the specific mechanism of TAI. Direct
injury to neuronal cell bodies and their dendritic fields, glial cells, or vasculature, as well
as elevated intracranial pressure and secondary ischemia, could have secondary effects
on axons. These limitations can be significantly overcome in the optic nerve stretch
model. The optic nerve shares similar properties with white matter tracts within the brain,
including poor regenerative capacity, myelin sheath structure, and the presence of
oligodendrocytes (Cho et al., 2005; Hirano and Lena, 1995).

Axonal transport disruption after optic nerve stretch
The characteristics of axonal injury and degeneration seen after optic nerve
stretch mimic those found in established whole brain models of axonal injury, as well as
in human brain after TBI (Ma et al., 2009). Axonal swellings and bulbs are hallmarks of
TAI, and are thought to result from primary axonal transport disruption. In a murine optic
nerve stretch model, approximately 60% of axons failed to transport fluorogold from the
superior colliculus (Saatman et al., 2003). Retrograde axonal transport of fluorogold was
also impaired after experimental closed head injury in mice (Creed et al., 2011).
We were unable to show an improvement of retrograde axonal transport of
fluorogold after unilateral optic nerve stretch in animals given MDL-28170. Maxwell and
Graham (1997) demonstrated in the guinea pig optic nerve stretch model that there was
a dramatic loss of microtubules throughout axons 15 minutes post-injury. As
microtubules are known calpain substrates, an attractive hypothesis is that calpains
proteolyze microtubules, resulting in transport disruption. Our short-duration intense
therapy was targeted toward these early events. It may be necessary to inhibit calpains
for a longer duration.
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Limitations
We attempted to maximize the total dose of MDL-28170 by giving a 30 mg/kg
bolus followed by 15 mg/kg/hr infusion for 2.5 hrs. However, it is possible that the
resulting MDL-28170 concentration in the optic nerve axons was not sufficient to inhibit
pathologic calpain activity. Based on available evidence, we do not believe a higher
dose would be feasible in our model. During the initial MDL-28170 bolus, approximately
15-20% of rats had transient bradycardia and respiratory difficulty, and deaths occurred
when we tried to increase the infusion rate. These adverse effects were not seen when
DMSO was administered alone. In rabbits, a 60 mg/kg IV infusion of MDL-28170 over 10
minutes has been reported to be lethal (Neumar et al., 1998). MDL-28170 doses higher
than 30 mg/kg IP were lethal in mice. (Üçeyler et al., 2010).
The results of this study do not demonstrate a statistically significant decrease of
Ab38 labeling 30 minutes after optic nerve stretch in animals treated with MDL-28170
versus DMSO alone. However, half of the animals in the DMSO group had high Ab38
intensity in the stretched nerve, whereas all the animals in the MDL-28170 group had
similar intensity in the stretched and contralateral uninjured nerve. The variability of
pathologic calpain activity in the DMSO group highlights a limitation of the model, which
makes it more difficult to find a statistically significant treatment effect.

Conclusions
There is growing evidence that inhibiting calpains in experimental TBI models
protects against axonal pathology. However, it is not known where in the neuron these
inhibitors exert their effects. We attempted to address this question by using a wellstudied calpain inhibitor in an in vivo model of isolated axonal stretch injury. Using this
model, we were not able to detect a therapeutic benefit of short duration intravenous
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MDL-28170 therapy. It is believed that after mild TBI, long white matter tracts are
preferentially injured, and this loss of “connectivity” may underlie the persistent
symptoms seen in this group of patients. Axonal injury is offered as an explanation as to
why some patients after trauma are comatose even when their brains lack mass lesions
(Gennarelli et al., 1982). Therefore, continued work is needed to determine if
mechanisms of axonal degeneration differ between isolated white matter injury and
predominantly gray matter or mixed injury. If significant differences exist, then it might be
necessary to individualize therapeutic strategies to target the appropriate injury pathway.
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Figure 4.1.
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Fig. 4.1. Effect of intravenous MDL-28170 on calpain-mediated α-spectrin degradation
30 minutes after optic nerve stretch. (A) Ab38 immunolabeling for calpain-cleaved αspectrin proteolytic fragments in 10 µm thick longitudinal sections of optic nerves.
Animals received MDL-28170 or DMSO vehicle alone prior to unilateral optic nerve
stretch. Images near the optic chiasm were captured at 400x magnification. Arrows
highlight discrete Ab38 labeled axonal profiles in an animal treated with MDL-28170,
whereas in regions of intense Ab38 labeling in DMSO animals, labeling is more diffuse.
Scale bar = 20 µm. (b) Semiquantitative assessment of Ab38 staining intensity.
Horizontal bar represents the group mean.
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Figure 4.2.
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Fig. 4.2. Effect of intravenous MDL-28170 on axonal transport disruption 4 days after
optic nerve stretch. (A) Representative images captured at 200x of retinal flat mounts
immunolabeled for tuj1 antibody (neuron-specific class III β-tubulin), a marker of RGCs
(green). Fluorogold is pseudocolored red. Animals received MDL-28170 or DMSO
vehicle alone prior to unilateral optic nerve stretch and fluorogold injection. Scale bar =
50 µm. (B) Quantification of RGCs that were able to transport fluorogold from the
superior colliculus after unilateral optic nerve stretch. Horizontal bar represents the
group mean. *p=0.002 when comparing uninjured and injured DMSO retinas.
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Calpastatin overexpression protects axonal
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injury
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ABSTRACT
Traumatic brain injury (TBI) causes substantial morbidity and mortality worldwide.
A key component of both mild and severe TBI is diffuse axonal injury. Except in cases of
extreme mechanical strain, when axons are torn at the moment of trauma, axonal stretch
injury is characterized by early cytoskeletal proteolysis, transport disruption, and
secondary axotomy. Calpains, a family of Ca2+-dependent proteases, have been
implicated in this pathologic cascade, but direct in vivo evidence is lacking. To test the
hypothesis that calpains play a causal role in axonal stretch injury in vivo, we used our
rat optic nerve stretch model following adeno-associated viral (AAV) vector mediated
overexpresssion of the endogenous calpain inhibitor, calpastatin, in optic nerve axons.
AAV vectors were designed for optimal expression of human calpastatin
(hCAST) in retinal ganglion cells (RGCs). Calpain inhibition by the overexpressed
transgene was then confirmed in primary cortical cultures. Finally, we performed bilateral
intravitreal injections of AAV vectors expressing hCAST or the reporter protein ZsGreen
3 weeks prior to unilateral optic nerve stretch. Immediately after stretch injury, fluorogold
was injected into the superior colliculi for assessment of retrograde axonal transport.
Rats were euthanized 4 days after stretch injury. Both hCAST and ZsGreen were
detected in axons throughout the optic nerve to the chiasm. Calpastatin overexpression
partially preserved axonal transport after stretch injury (58.3±15.6% reduction in
fluorogold labeling relative to uninjured contralateral control in ZsGreen expressing
RGCs versus 33.8±23.9% in hCAST expressing RGCs; p=0.038). These results provide
direct evidence that calpains within axons play a causal role in transport disruption after
in vivo stretch injury.
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HIGHLIGHTS
(1) Viral vector mediated transduction of retinal ganglion cells in combination with the
optic nerve stretch model is a promising tool to explore the molecular mechanisms of
axonal stretch injury in vivo.
(2) In vivo optic nerve stretch results in axonal swellings and bulbs and retrograde
transport disruption.
(3) Calpain inhibition within axons protects retrograde axonal transport after isolated
axonal stretch injury in vivo.

KEYWORDS
adeno-associated viral vectors; axonal injury; axonal transport; calpains; calpastatin;
traumatic brain injury

ABBREVIATIONS
AAV, adeno-associated viral/virus; APP, amyloid precursor protein; CAST, calpastatin;
DAPI, 4,6-diamidino-2-phenylindole; DIV, days in vitro; GAPDH, glyceraldehyde 3phosphate dehydrogenase; HRP, horseradish peroxidase; hCAST, human calpastatin;
IV, intravenous; NFH, neurofilament heavy subunit; RGC, retinal ganglion cell; TAI,
traumatic axonal injury; TBI, traumatic brain injury
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INTRODUCTION
Worldwide, traumatic brain injury (TBI) leading to death or hospitalization is
estimated to afflict over 10 million people annually, and is predicted to surpass many
diseases as the major cause of death and disability by the year 2020 (Hyder et al.,
2007). Traumatic axonal injury (TAI) is implicated in the cognitive dysfunction seen after
mild TBI, as well as coma and mortality after severe TBI (Gennarelli et al., 1982;
Medana and Esiri, 2003). Blunt brain trauma produces a rapid elongation or deformation
of axons that may lead to progressive axolemmal and cytoskeletal damage culminating
in secondary axotomy (Jafari et al., 1997; Maxwell and Graham, 1997; Povlishock and
Katz, 2005; Povlishock et al., 1997; Saatman, et al., 2003). Mechanical deformation of
axons results in focal impairment of axonal transport with subsequent accumulation of
transported proteins and organelles. Accumulations of amyloid precursor protein (APP),
which undergoes fast anterograde transport, are seen as early as 2 hours after TBI in
humans (Blumbergs et al., 1995; McKenzie et al., 1996). Anterograde transport of
intravitreally injected horseradish peroxidase (HRP) and retrograde transport of
fluorogold after its injection into the superior colliculi, are both disrupted after optic nerve
stretch, an in vivo model that isolates mechanical strain primarily to axons (Gennarelli et
al., 1989; Ma et al., 2012; Saatman et al., 2003). Similarly, HRP accumulations are also
seen in a more diffuse brain injury model, fluid percussion injury in cats (Povlishock et
al., 1983).
Post-traumatic calpain activity within axons has been proposed to contribute to
cytoskeletal degradation, neurofilament compaction, and transport disruption (Büki and
Povlishock, 2006; Büki et al., 2003; Saatman et al., 2010). Calpains are a family of
nonlysosomal Ca2+-dependent proteases involved in cytoskeletal remodeling, signal
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transduction, apoptosis, and necrosis (Zatz and Starling, 2005). The two ubiquitous
calpains, µ- and m-calpain, are heterodimeric peptides, consisting of different catalytic
isoforms and a common regulatory subunit. They differ in the Ca2+ concentration
required for in vitro activity. The family also consists of calpastatin (CAST), an
endogenous inhibitor of both µ- and m-calpain that does not inhibit proteases in any
other family (Goll et al., 2003). Calpain activity measured by immunolabeling for calpaincleaved α-spectrin (Ab38) is observed in axons in the pyramidal tracts and medial
lemnisci 15 minutes after head acceleration injury in rats (Büki et al., 1999b). Early
axonal calpain activity after fluid percussion injury has been reported (Saatman et al.,
1996). After optic nerve stretch, elevated calpain activity is detectable 20-30 minutes
post-injury (Ma et al., 2012; Saatman et al., 2003).
Pharmacologic inhibition of central nervous system calpain activity remains
challenging, and there is no pharmacologic inhibitor completely specific for calpains (Goll
et al., 2003). Nevertheless, various calpain inhibitors have demonstrated neuroprotection
in diffuse TBI models (Saatman et al., 2010). MDL-28170 is perhaps the most well
studied calpain inhibitor. Even though specific for calpains, it also has significant activity
against cathepsin B (Markgraf et al., 1998). A single intravenous (IV) bolus (30 mg/kg) of
MDL-28170 reduces axonal pathology in rodent TBI models (Ai et al., 2007; Büki et al.,
2003; Czeiter et al., 2009). In contrast, in the optic nerve stretch model, intensive MDL28170 therapy does not protect retrograde transport of fluorogold (Ma et al., 2012). It is
not known whether pharmacologic protection seen in the diffuse TBI models occurs at
the level of the axons, supra-axonal structures or both as neither the injury nor therapy is
selective to axons.
In contrast to pharmacologic inhibitors, calpastatin is completely specific for
calpains (Goll et al., 2003). Calpastatin overexpression has been used to protect
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hippocampal neurons after kainite injection (Higuchi et al., 2005; Rao et al., 2008;
Takano et al., 2005) and transient global ischemia (Cao et al., 2007). Our strategy was
to overexpress calpastatin in retinal ganglion cell (RGC) axons prior to optic nerve
stretch. We hypothesized that calpastatin overexpression within axons would protect
retrograde transport. Determining the specific role of calpains in isolated axonal injury
may have important implications for targeting pathologic calpain activity after TBI and
spinal cord injury.
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MATERIALS AND METHODS
All animal procedures were performed in accordance with National Institutes of
Health guidelines for the care and use of laboratory animals and were approved by our
Institutional Animal Care and Use Committee. All appropriate bio-safety procedures
were followed in handling the adeno-associated viral (AAV) vectors.

Viral vector generation
Cloning and generating the recombinant AAV vectors (serotype 2) were
performed by the Vector Core at the University of Pennsylvania. The human calpastatin
(hCAST; clone ID 3878564 from Open Biosystems, Huntsville, AL) or ZsGreen gene
(Clontech, Mountain View, CA) was cloned into pENN.AAV.CB7, an AAV packaging
plasmid, downstream of the CB7 promoter. CB7 is a chicken ß-actin promoter with
cytomegalovirus enhancer elements. The viral genomes encoded in both constructs
were verified by sequencing analysis prior to vector production. Generation of the AAV
vectors has been previously described (Gao et al., 2002).

Primary cortical neuron culture
Cortices from E17-19 Sprague-Dawley rat embryos were trypsinized in
DMEM (BioWhittaker-Lonza, Basel, Switzerland) containing 0.027% trypsin for 15 min.
They were triturated in media consisting of DMEM supplemented with 10% fetal calf
serum (Hyclone, Logan, UT). Dissociated cells were plated at a density of ~260
cells/mm2 in 24 well plates with glass coverslips or ~620 cells/mm2 in 35-mm dishes.
Dishes and coverslips were coated with poly-L-lysine (Peptides International, Louisville,
KY). Cultures were maintained in serum-free Neurobasal medium (Life Tech., Grand
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Island, NY) supplemented by B27 (Life Tech.) in a humidified 5% CO2 incubator at 37ºC.
Mitotic inhibitors and antibiotics were not used.

AAV vector testing in primary cortical neuron culture
Neuronal cultures 7 days in vitro (DIV) were transduced with 6 x 109 (24 well
plate) or 3.3 x 1010 genome copies (35-mm dish) of AAV vectors expressing either
ZsGreen (AAV.ZsGreen) or hCAST (AAV.hCAST). Fourteen days later, cultures were
fixed with 4% paraformaldehyde, immunolabeled for hCAST (MAB3084; 1:4000;
Millipore, Billerica, MA), and counter-stained with 4,6-diamidino-2-phenylindole (DAPI)
nuclear label. MAB3084 detects human, but not rat, CAST. Additional cultures were
harvested and sonicated in homogenization buffer (25 mM HEPES, ph 7.4, 1 mM EDTA,
0.1% CHAPS). Protein concentration was quantified using the Bradford assay. Proteins
were separated by SDS-PAGE on a 4-20% tris-glycine gel, transferred to a nitrocellulose
membrane, and probed for hCAST (MAB3084; 1:1000) and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH; PA1-988; 1:1000; Thermo Scientific, Rockford, IL). Blots were
visualized using enhanced chemiluminescence. HRP-conjugated secondary antibodies
and enhanced chemiluminescence substrate were purchased from Perkin Elmer
(Waltham, MA).
Functional hCAST overexpression was assessed by measuring calpastatin
activity in transduced and nontransduced cell extracts. Cultures (3-5 per condition) were
harvested as described above. Protein concentrations of the cell extracts were adjusted
to 3 µg/µl. Extracts were heated to 90ºC for 5 min then centrifuged at 16,000 g at 4ºC for
20 min. Reactions contained 5 µl of supernatant, 10 nM human erythrocyte calpain 1
(EMD, Gibbstown, NJ), 200 µM Suc-Leu-Tyr-MNA (MP Biomedicals, Solon, OH), and
195 µl of the homogenization buffer with 5 mM B-mercaptoethanol. The reaction
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performed at room temp, was started by adding CaCl2 to a final concentration of 5 mM.
Time-dependent substrate proteolysis, which results in increasing fluorescence, was
measured on a microplate reader (Turner Biosystems, Sunnyvale, CA; 365 nm
excitation, 410-460 nm emission). All samples were assayed in triplicate.

Intravitreal injection of AAV vectors
Adult male Long-Evans rats (130-160 g) underwent isoflurane anesthesia
followed by application of 0.5% proparacaine eyedrops. Using an operating microscope
(Zeiss Opmi MD, Thornwood, NY), a superotemporal conjunctival incision was made to
expose the sclera posterior to the lens. A pilot hole was made with a 30 gauge needle
followed by the introduction of the tip of a glass micropipette containing the viral vector.
The micropipette was connected to a 5 µl glass syringe by polyethylene tubing filled with
mineral oil. Both eyes in the same animal were injected with the same vector (4 µl at a
concentration of 1.13 x 1012 genome copies/ml).

Optic nerve stretch
One blinded investigator performed all surgeries. In each operative day,
approximately half of the rats were transduced with either AAV.hCAST or AAV.ZsGreen.
Three weeks after intravitreal injection, rats underwent unilateral optic nerve stretch as
described previously (Ma et al., 2012). In brief, rats were anesthetized with isoflurane
and placed in a stereotactic head holder that was positioned on the injury device. Body
temperature was maintained at ~37.5ºC and pulse ox between 94-98%. A flexible thin
ring-shaped plastic sling, which had a continuous loop of 4-0 monofilament nylon suture
secured to it at 4 places 90° apart, was placed behind the eye. The monofilament nylon
loop was then attached to the optic nerve stretch device. To ensure consistent loading, a
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12 gram preload, measured by a force transducer (LFS 270; Cooper Instruments &
Systems, Warrenton, VA), was placed on the nerve. The magnitude of the displacement
was controlled by a micromanipulator that adjusts the distance traveled by the solenoid
piston. The 5.5 mm magnitude of optic nerve stretch reported here refers to piston
displacement. The distance the piston traveled was significantly more than the actual
stretch of the optic nerve (Bain and Meaney, 2000; Ma et al., 2009). Immediately after
obtaining the preload, the solenoid was triggered to produce a rapid elongation of the
nerve. Two animals were excluded as the optic nerves tore, leaving 7 Zsgreen and 8
hCAST rats for analysis.
After injury, erythromycin ophthalmic ointment was applied to both eyes, and the
lids of the injured side were sutured together for 2 days to prevent corneal drying. The
contralateral uninjured eye and optic nerve were used as controls. Animals received
fluorogold injections immediately after optic nerve stretch.

Assessment of fluorogold labeling of RGCs
To label RGCs that were capable of retrograde transport, animals received
bilateral injections of fluorogold (Fluorochrome, Denver, CO) into each superior colliculus
as previously described (Ma et al., 2012). Four days later, rats were reanesthetized and
transcardially perfusion fixed with cold 1x PBS followed by cold 4% paraformaldehyde in
0.1 M phosphate buffer (pH 7.4). Retinas were removed from the eye and postfixed for
2-3 hours in 4% paraformaldehyde (4°C). After washing with 1x PBS, retinal flat mounts
were blocked in 10% goat serum, 1% BSA, and 0.2% triton x-100 in 1x PBS for 1 hr at
room temp. Retinas were incubated overnight at 4°C with an antibody directed against
neuronal class III ß-tubulin (1:5000; PRB-435P; Covance, Emeryville, CA), which labels
RGCs (Cui et al., 2003), and/or MAB3084 (1:4000). After further washes, retinas were
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incubated in alexa secondary antibodies (Molecular Probes, Eugene, OR) for 2 hours at
room temp. Retinas were washed and coverslipped with Fluoromount G (Electron
Microscopy Sciences, Hatfield, PA).
The retinas were flat mounted and viewed with a fluorescent microscope (Leica
DM4500B; Buffalo Grove, IL). Camera and microscope settings for fluorogold were kept
constant across all retinas. Images were taken at 400x mag in 3 areas—1/6, 3/6 and 5/6
of the retinal radius from the center of the retina—in the region with the highest AAV
transduction. The “levels” tool in Adobe Photoshop was used in a standardized way to
increase hCAST and fluorogold contrast and brightness. The black and white levels
sliders were adjusted to outside the image histogram so the histogram was extended to
fill the entire tonal range. Scoring was performed by a blinded observer using Adobe
Photoshop and National Institutes of Health ImageJ. Approximately 30-35 transduced
RGCs per retinal area were scored for fluorogold. The percentages determined for the
central, middle and peripheral areas were averaged, and that number is reported here.
Preliminary work suggested that a smaller percentage of hCAST expressing RGCs
labeled with fluorogold compared to ZsGreen expressing RGCs (data not shown). To
control for this potential baseline difference, we decided a priori to compare the
percentage loss of fluorogold labeling of transduced RGCs as compared to its
contralateral uninjured side.

Assessment of RGC counts after viral transduction and optic nerve stretch
To assess RGC counts 4 days after optic nerve stretch, immunolableled retinas
were divided into thirds and images were taken at 200x mag in 3 areas—1/6, 3/6 and 5/6
of the retinal radius from the center of the retina—in each of the 3 regions. Two of the 3
regions were randomly selected, and RGCs (PRB-435P positive cells) were counted by
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a blinded observer. RGCs obscured by axonal fascicles were not counted. The counts
from the 6 images were summed and reported here. The total area of the retina scored
was 1.1 mm2.

Immunohistochemistry of optic nerves
After perfusion fixation, the optic nerves were removed from the head and
postfixed for 2-3 hours in 4% paraformaldehyde (4°C). Nerves were subsequently
cryoprotected in 30% sucrose. The right and left optic nerves of the same animal were
frozen in the same OCT block, and were cut longitudinally into 14 µm thick sections on a
cryostat.
After drying, slides were blocked in 3% goat serum and 0.1% triton x-100 in 1x
PBS (pH 7.2). The tissue sections were incubated overnight at 4°C with MAB3084
(1:1000), sc-20779 (detects both rat and human CAST; 1:250; Santa Cruz Biotech.,
Santa Cruz, CA), and/or SMI-32 (1:1000; Sternberger Monoclonals, Lutherville, MD).
SMI-32 reacts with a non-phosphorylated epitope on neurofilament heavy subunit (NFH).
Neurofilament accumulation within axons highlights swellings and bulbs (Ma et al., 2009;
Saatman et al., 2003). After further PBS rinses, the slides were incubated with alexa
secondary antibodies for 1 hour at room temp. Slides were rinsed and coverslipped with
Fluoromount G.

Harvesting of optic nerve homogenates for western blot
Three weeks after intravitreal injection of viral vectors, rats were anesthetized
with isoflurane and decapitated. The optic nerves were homogenized in 50 mM tris, 150
mM NaCl, 1% triton, and 2 mM EGTA (pH 7.0) with protease inhibitors (Roche,
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Indianapolis, IN). Western blot for hCAST and GAPDH was performed as described
above.

Statistical Analysis
One-way ANOVA was performed to compare the slopes (fluorescence over time)
generated by calpain proteolysis of the fluorogenic substrate. Pairwise comparisons
within the interaction space were specified a priori and were accomplished using the ttest and appropriate pooled variance. There were 3 pre-planned comparisons: ZsGreen
versus nontransduced cultures, hCAST versus ZsGreen cultures, and hCAST versus
nontransduced cultures. To adjust for 3 pairwise comparisons the p-value was set at
0.017 for statistical significance. The percentage loss of fluorogold labeling in ZsGreen
and hCAST transduced RGCs after optic nerve stretch were compared using Student’s
t-test. A p-value < 0.05 was considered statistically significant. ANOVA in repeated
measures was used for all other analyses. A p-value < 0.05 for main effects and <0.2 for
the interaction space were considered statistically significant. For the fluorogold labeling
experiment, there were 4 pre-planned comparisons: ZsGreen versus hCAST uninjured,
ZsGreen injured versus uninjured, hCAST injured versus uninjured, and ZsGreen versus
hCAST injured. For 4 pairwise comparisons a p<0.013 was considered significant. Data
are presented as means and standard deviations. All data were analyzed using SAS
statistical software (version 9.2, SAS Institute, Cary, NC).
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RESULTS
Expression of functional hCAST in primary cortical cultures
AAV vectors were generated to express hCAST or the fluorescent marker protein
ZsGreen and initially characterized in primary cortical neuronal cultures. Cultures were
transduced at 7 DIV. Nontransduced cultures served as controls. At 21 DIV, the cultures
were analyzed by immunohistochemistry, Western blot, and CAST activity assay. Two
weeks after AAV vector transduction, there was robust expression of ZsGreen and
hCAST (Fig. 1). To determine if hCAST was functional, we used a fluorogenic substrate
microplate assay (Fig. 1B). Proteolysis of Suc-Leu-Tyr-MNA resulted in increasing
fluorescent signal. ZsGreen cultures were not significantly different than nontransduced
ones (slopes 17.9±0.7 versus 18.6±0.4, respectively; p=0.15). Lysates from hCAST
cultures robustly inhibited exogenous calpain activity as compared to ZsGreen and
nontransduced cultures (slope for hCAST: 1.0±0.7; p<0.0001). Omitting exogenous
calpain, fluorogenic substrate or CaCl2 resulted in no change in fluorescence (data not
shown). These results demonstrated that our AAV vectors effectively transduced primary
cortical cultures resulting in expression of functional hCAST or ZsGreen.

Expression of hCAST and ZsGreen in RGC somata and axons
After in vivo rat optic nerve stretch, the highest levels of early calpain activity as
well as the greatest density of swellings and bulbs occurred near the optic chiasm (Ma et
al., 2012, 2009). Therefore, we confirmed that overexpressed hCAST in RGCs
undergoes anterograde axonal transport to the prechiasmatic optic nerve.
Three weeks after intravitreal injection of AAV.ZsGreen or AAV.hCAST, rats
were sacrificed for immunolabeling of the retina and prechiasmatic optic nerve, as well
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as immunoblotting of the optic nerve. ZsGreen and hCAST were detected in RGC
somata, as well as axons near the optic chiasm (Fig. 2). Immunoblotting confirmed
hCAST in optic nerves (Fig. 2B).

Rat optic nerve stretch results in axonal swellings and bulbs
Four days after unilateral optic nerve stretch, there were axonal accumulations of
ZsGreen and hCAST that morphologically appeared to be swellings and bulbs (Fig. 3).
There appeared to be significantly more ZsGreen accumulations than hCAST, however
this difference was not quantified (see limitations). Neither type of accumulation was
present in the contralateral uninjured optic nerves. We immunolabeled optic nerve
sections with SMI-32, a classic marker of swellings and bulbs. A subset of ZsGreen and
hCAST accumulations also labeled with SMI-32 (Fig. 3).

Human CAST ameliorates retrograde axonal transport disruption after optic nerve
stretch
Axonal stretch injury results in focal disruptions of transport presumably at sites
of axonal swellings. Therefore, our goal was to inhibit local calpain activity within axons
by hCAST overexpression, and examine the effect on axonal transport disruption after
stretch injury. Three weeks after intravitreal injection of AAV vectors in both eyes,
unilateral optic nerve stretch was performed. This was immediately followed by injection
of fluorogold into the bilateral superior colliculi. Retinal ganglion cells with intact
retrograde axonal transport accumulated fluorogold in their somata. Quantification of
RGCs revealed no evidence of RGC loss 4 days after optic nerve stretch regardless of
vector treatment (p=0.55; Fig. 4A and 4B).
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To determine the effect of hCAST expression on axonal transport after stretch
injury, we quantified the percentage of transduced RGCs (ZsGreen+ or hCAST+) that
labeled with fluorogold. On the uninjured side, 69.4±9.6% and 57.2±11.5% of ZsGreen+
and hCAST+ RGCs, respectively, had fluorogold labeling (p=0.02; Fig. 4C). This result is
consistent with our preliminary work that suggests decreased fluorogold labeling of
hCAST transduced RGCs. After stretch injury, 28.3±9.2% of ZsGreen+ RGCs labeled
with fluorogold (p<0.0001 versus uninjured contralateral retina) while 37.7±12.9% of
hCAST+ RGCs labeled with fluorogold (p=0.001 versus uninjured contralateral retina).
This difference in the absolute percentage of ZsGreen+ versus hCAST+ RGCs that label
with fluorogold after optic nerve stretch was not statistically significant (p=0.07).
However, when quantified relative to fluorogold labeling of transduced RGCs in the
uninjured contralateral retinas, optic nerve stretch caused a 58.3±15.6% reduction in
fluorogold labeling of ZsGreen+ RGCs versus a 33.8±23.9% in hCAST+ RGCs
(p=0.038; Fig. 4D). This statistically significant difference supports our hypothesis that
calpains are causally responsible for transport disruption after mechanical stretch of
axons.
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DISCUSSION
We were able to demonstrate statistically significant protection of retrograde
axonal transport after isolated axonal stretch injury with overexpression of the
endogenous calpain inhibitor calpastatin. Our current results extend earlier studies that
demonstrated axonal protection with pharmacologic calpain inhibitors, but were limited
by potential off target effects and the use of TBI models with mixed gray and white
matter injury.

Viral vector strategy to study axonal injury mechanisms in vivo
Pharmacology as a strategy to modulate the molecular mechanisms of neuronal
and axonal injury after trauma has potentially significant limitations, such as limited
blood-brain barrier penetration, poor molecular target specificity, and drug toxicity. The
viral vector approach offers several theoretical advantages. The delivery location, virus
type, and promoter may allow for more selective manipulation of specific neuronal or
glial populations. Viral vectors have been previously used to manipulate neurons prior to
experimental TBI (Conte et al., 2008). In our case, because the transgene is required to
exert local effects in the axonal compartment, we relied on the native axonal transport
machinery. For proteins that are normally excluded from axons, selective subcellular
targeting of expressed proteins to axons, which has been described by Stowell and
Craig (1999), may be necessary.
In the brain, it is often difficult to trace back large groups of axons of interest to
specific neuronal populations as large white matter tracts often connect myriad and
spatially diverse cell populations, thus limiting experimental manipulation and
interpretation. This can be overcome in the optic nerve, which shares similar properties
with white matter tracts within the brain, including poor regenerative capacity, myelin
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sheath structure, and the presence of oligodendrocytes (Cho et al., 2005, Hirano and
Lena, 1995). The axons are relatively homogenous in size, uni-directional and have welldefined targets. Manipulating the parent neurons is technically straightforward and a
large percentage of RGCs can be transduced after a single intravitreal injection (Martin
and Quigley, 2004). In this report, we have demonstrated that transgene delivery to
axons can be readily achieved in the optic nerve. As our injury model preferentially
affects axons, this model in combination with our therapeutic AAV vector strategy
allowed us to explore the mechanisms underlying axonal dysfunction after TBI.

ZsGreen and hCAST accumulates in axonal swellings and bulbs
In our study, we demonstrated that 4 days after optic nerve stretch, there were
accumulations of 2 different exogenous proteins, ZsGreen and hCAST, which occurred
at sites where axonal transport is presumably disrupted. Many of these swellings and
bulbs labeled with the neurofilament marker SMI-32, classically used to detect swellings
and bulbs (Ma et al., 2009; Saatman et al., 2003). If hCAST were completely protective
after nerve stretch, we would not expect hCAST co-labeling with SMI-32 at axonal
swellings. However, our optic nerve results are consistent with the incomplete protection
seen in our main outcome measure, fluorogold labeling of RGCs.
Examining optic nerves was useful as it allowed us to draw two conclusions.
First, overexpression of ZsGreen or hCAST did not result in overt morphological injury of
optic nerve axons. Second, stretched nerves in all rats were injured as they all had SMI32 immunoreactive swellings and bulbs, which were not seen in contralateral uninjured
nerves.
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Pathologic calpain activity contributes to retrograde transport disruption after
optic nerve stretch
Our main outcome measure was axonal function as opposed to classic
histopathologic changes (axonal swellings and bulbs) as it has been proposed that a
significant fraction of normal appearing axons may be rendered dysfunctional after
trauma (Yuen et al., 2009). In this current study, unilateral optic nerve stretch disrupted
fluorogold transport in 58.3±15.6% of ZsGreen+ RGCs, which is consistent with previous
investigations (Ma et al., 2012; Saatman et al., 2003). After mouse optic nerve stretch,
disruption of retrograde axonal transport occurs early and appears to be complete and
permanent (Saatman et al., 2003). Stretch injury probably does not simply delay
retrograde transport of fluorogold.
Human CAST overexpression ameliorated retrograde transport disruption after
stretch injury. The lack of complete protection by hCAST may be due to incomplete
calpain inhibition, or the contribution of other injury mechanisms such as the microtubule
destabilizing effects of elevated intraaxonal Ca2+ (Gaskin et al., 1975; Job et al., 1981;
Keith et al., 1983; Maxwell et al., 1997) or other proteases. For example, caspase
activity has been detected after experimental TAI (Büki and Povlishock, 2006; Büki et al.,
2000).
A number of other studies have suggested that calpains play a role in TAI. Rats
given an IV bolus of the calpain inhibitor MDL-28170 (30 mg/kg) 30 minutes prior to fluid
percussion or impact head acceleration injury demonstrate reduced axonal swellings
and bulbs and neurofilament compaction in brainstem fiber tracts (Büki et al., 2003),
improved axolemmal integrity of the corticospinal tract (Czeiter et al., 2009), and
structural and electrophysiological protection of the corpus callosum (Ai et al., 2007).
Interpretation of these results requires caution though as MDL-28170 also inhibits
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proteases other than calpains (Markgraf et al., 1998). As injury to supraaxonal structures
and physiologic derangements after TBI may secondarily cause axonal dysfunction and
degeneration, it is not clear if the protective effect of the calpain inhibitor occurs directly
within axons. We attempted to address this question in an earlier investigation by using
a model that primarily isolates mechanical strain to axons (Ma et al., 2012). Rats
received a 30 mg/kg IV bolus of MDL-28170 30 minutes prior to unilateral optic nerve
stretch. After the bolus, animals were infused the drug at 15 mg/kg/hr over the following
2.5 hrs. Despite the early intensive therapy, which was designed to match the time
course of early calpain activity (Saatman et al., 2003), we were unable to protect
retrograde axonal transport measured 4 days after optic nerve stretch. It was not
established if the duration of treatment or the intraaxonal concentration of MDL-28170
was sufficient to block pathologic calpain activity.
The mechanism by which calpains disrupt axonal transport has not been clearly
established. The ultrastructural pathology seen after TAI is microtubule loss and
neurofilament misalignment and compaction. Microtubule loss has been hypothesized to
impair axonal transport (Maxwell, 1996; McCracken et al., 1999; Saatman et al., 2003).
Maxwell and Graham (1997) demonstrated that 15 minutes after guinea pig optic nerve
stretch, there was a dramatic loss of microtubules throughout axons. By 2 hours,
internodal axonal swellings containing significantly reduced numbers of microtubules
had developed. Calpains may directly proteolyze tubulin and tau (Billger et al., 1988;
Johnson et al., 1989; Siman and Noszek, 1988), which is important for microtubule
stability (Amos and Schlieper, 2005). It is not known if calpains contribute to microtubule
loss in vivo as elevated Ca2+ has been shown to depolymerize microtubules directly or
via activation of calmodulin (Gaskin et al., 1975; Job et al., 1981; Keith et al., 1983;
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O'Brien et al., 1997). Axonal stretch injury results in an acute rise in intraaxonal Ca2+
(Iwata et al., 2004; Ma et al., 2012; Staal et al., 2010).
Neurofilament misalignment and compaction have been suggested to impair
axonal transport (Christman et al., 1994; Smith and Meaney, 2000). Disruption of the
ordered arrangement of neurofilaments occurs in human diffuse axonal injury (Christman
et al., 1994). RMO14 is a commonly used marker of early axonal injury, presumably due
to calpain proteolysis of sidearms on the neurofilament medium subunits (Büki et al.,
2003). RMO14 immunoreactivity is prominent in the corticospinal tract and medial
longitudinal fasciculus in rodent head impact acceleration injury (Büki et al., 2003; Stone
et al., 2001). In the corticospinal tract, RMO14 immunoreactive axons do not consistently
stain with amyloid precursor protein (APP), which is a marker of swellings and bulbs, nor
have evidence of organelle pooling, suggesting that neurofilament sidearm modifications
may not directly impair axonal transport (Stone et al., 2001). The functional
consequence of neurofilament sidearm modifications remains unclear.

Limitations
At baseline, a lower percentage of transduced RGCs labeled with fluorogold than
was expected based on our preliminary unpublished data and work by others
(Barnstable and Drager, 1984; Salinas-Navarro et al., 2009). Nevertheless, one blinded
observer scored all retinas for fluorogold labeling. Because we did not attempt to
formally answer whether viral transduction independently affected retrograde transport,
speculating on why this may be so would be premature. There was a trend toward
differential fluorogold labeling of uninjured ZsGreen and hCAST RGCs (69.4±9.6%
versus 57.2±11.5%; p=0.02). Because of multiple comparisons p<0.013 was considered
significant. As this discrepancy may have obscured a treatment effect if absolute
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numbers were compared, we decided a priori to use the contralateral uninjured side in
each animal as an internal control for baseline fluorogold labeling of transduced RGCs.
The potential baseline difference in fluorogold labeling of ZsGreen+ and hCAST+ RGCs
may be due to an intrinsic property of hCAST. Calpains may regulate key aspects of
retrograde axonal transport. E-64 and leupeptin, which inhibit various proteases
including calpains, prevent the anterograde-retrograde conversion of axonally
transported vesicles (Sahenk and Lasek, 1988). Differential fluorogold labeling may also
result from a more generalizable consequence of protein overexpression. For example,
overexpressed proteins may require different molecular machinery for their own axonal
transport, thereby “crowding out” other proteins that rely on the same transport
mechanisms.
Quantification of ZsGreen and hCAST swellings and bulbs was not performed for
several reasons. First, the transduction efficiency of RGCs after intravitreal injection of
AAV vectors was variable. Second, even assuming equal transduction efficiency of the
two viral vectors, significantly more transduced axons in ZsGreen+ optic nerves than
hCAST+ nerves would be detectable. It is easier to identify ZsGreen labeled axons as
ZsGreen is intrinsically fluorescent and has high signal-to-noise. Third, their turnover
rates and anterograde transport speeds are unknown, which may influence the formation
and stability of swellings and bulbs identified using these two proteins. Given these
caveats, no attempt was made to quantify swellings or bulbs.
The variable and low transduction efficiency of the AAV vectors was a significant
limitation when developing strategies to quantify the direct effects of the two
overexpressed proteins on in vivo calpain activity after optic nerve stretch. Western blot
for calpain-cleaved α-spectrin (Ab38) of optic nerve homogenates would not have been
sensitive enough given the low transduction efficiency. In a previous study, we used
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Ab38 immunohistochemistry to demonstrate increased intra-axonal calpain activity 30
minutes after optic nerve stretch (Ma et al., 2012). However, it would have been
challenging to quantify the amount of Ab38 labeling in transduced axons, whose
diameters are approximately 1 µm, after optic nerve stretch. Given these limitations, we
did not address whether hCAST at the levels present within axons could inhibit in vivo
calpains using a more direct readout of calpain activity.

Conclusions
In summary, the present findings support our hypothesis that strain induced
calpain activity within axons directly impairs retrograde transport. By using viral vectormediated transduction of RGCs and the native anterograde transport machinery, we
were able to deliver the specific endogenous calpain inhibitor calpastatin to the site of
greatest injury (the prechiasmatic optic nerve). This approach in our model of optic nerve
stretch injury may help overcome the limitations of pharmacologic inhibitors and spur
future studies exploring the molecular mechanisms of TAI.
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Figure 5.1
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Fig. 5.1. Expression of functional hCAST in primary cortical neuronal cultures. (A) AAV
vectors expressing ZsGreen or hCAST were used to transduce primary cortical cultures
(7 DIV). At 21 DIV, cultures were immunolabeled for hCAST (MAB3084) and stained for
DAPI. Scale bar=20 µm. (B) In vitro analysis for calpastatin activity in cell extracts using
a fluorogenic substrate assay. Calpain proteolysis of Suc-Leu-Tyr-MNA, which results in
increasing fluorescence intensity, was almost completely blocked by hCAST
overexpression. Values are mean±SD for 3-5 cortical neuronal cultures per group
(*p<0.0001 versus nontransduced and ZsGreen expressing cells). Western blot
confirmed hCAST only in cultures transduced with AAV.hCAST.
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Figure 5.2
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Fig. 5.2. Expression of ZsGreen or hCAST in RGCs and their axons within the optic
nerve. (A) Rats were perfusion fixed 3 weeks after intravitreal injection of AAV.ZsGreen
or AAV.hCAST. Representative images of retinal flat mounts immunolabeled with
MAB3084 (hCAST) and/or an antibody directed against neuron-specific class III βtubulin that is used to label RGCs (PRB-435P). (B) Western blot of optic nerves
confirmed hCAST overexpression only after intravitreal injection of AAV.hCAST. (C)
Representative images of longitudinal sections of prechiasmatic optic nerves
immunolabeled with MAB3084. Scale bar=20 µm.
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Figure 5.3

Fig. 5.3. Disruption of axonal transport after unilateral optic nerve stretch. Rats received
bilateral intravitreal injections of AAV.ZsGreen or AAV.hCAST. After 3 weeks, unilateral optic
nerve stretch, immediately followed by fluorogold injection, was performed. Animals were
euthanized by perfusion fixation 4 days later. Longitudinal optic nerve sections were
immunolabeled with SMI-32, which is commonly used to detect swellings and bulbs, and/or
sc-20779 (CAST). Unilateral optic nerve stretch disrupted axonal transport, resulting in
accumulations of ZsGreen and hCAST, which frequently label with SMI-32. Scale bar=10
µm.
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Figure 5.4
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Fig. 5.4. Effect of hCAST on retrograde axonal transport disruption after optic nerve
stretch. (A) Rats received bilateral intravitreal injections of AAV.ZsGreen or AAV.hCAST.
After 3 weeks, unilateral optic nerve stretch, immediately followed by fluorogold injection,
was performed. Animals were euthanized by perfusion fixation 4 days later. (A)
Representative images of retinal flat mounts immunolabeled with an antibody directed
against neuron-specific class III β-tubulin (PRB-435P), and/or MAB3084 (hCAST).
Transduced RGCs labeled with fluorogold are marked with white circles, while those
without fluorogold are marked with black circles. Scale bar=10 µm. (B) Quantification of
RGCs (cells positive for neuron-specific class III β-tubulin) showed no apparent loss 4
days after stretch injury. (C) Percentage of transduced RGCs that label with fluorogold.
(D) Percent difference of fluorogold labeling of transduced RGCs between the injured
and contralateral uninjured sides. Human CAST overexpression ameliorated the
disruption of fluorogold transport after optic nerve stretch. For (B), (C), and (D), each
circle represents an individual retina, while horizontal bars represent means. *p<0.05
**p≤0.001

149

CHAPTER 6:
Discussion
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The work described in the previous chapters extends our understanding of how
calpains contribute to Wallerian degeneration and traumatic axonal injury (TAI).
Specifically, in Chapter 2, we showed that transection of axons in vivo resulted in robust
calpain activity on a time scale that is different in the CNS and PNS. Calpastatin
overexpression provided biochemical protection in transected PNS and CNS axons.
There was robust morphological protection in PNS axons, as well as structural
preservation of NMJs. However, synaptic function was not preserved. Interestingly,
previous investigators have described morphologically a type of degeneration in CNS
axons that is not seen in the PNS (Marques et al., 2003; Narciso et al., 2001). The
mechanistic basis of this difference is not known. Even though this was not formally
addressed, our data suggests that calpains do not appear to contribute to “dark”
degeneration. In Chapter 3, we developed and characterized the rat optic nerve stretch
model that primarily isolates mechanical strains to axons. Immediate, short-duration mild
hypothermia was axonal protective. The protective effect of hypothermia has been partly
ascribed to calpain inhibition (Büki et al., 1999a). We proceeded to specifically address
the role of calpains in TAI. In Chapter 4, pre-treatment with the pharmacologic calpain
inhibitor MDL-28170 did not protect retrograde axonal transport. However, as detailed in
Chapter 5, overexpression of CAST reduced retrograde axonal transport disruption by
42%. These discordant results may be due to the short duration or lack of effective intraaxonal drug concentration with intravenously delivered MDL-28170. Taken together,
these findings provide compelling support that calpains directly contribute to cytoskeletal
degeneration and axonal transport disruption in the diseased nervous system, and
suggest that calpains are necessary but not sufficient to protect synaptic function.
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Remaining questions and future directions
Our work raises important questions for future research into the role of calpains
in axonal injury. In this dissertation, we relied on calpastatin overexpression to modulate
calpain activity. Calpastatin inhibits both µ- and m-calpain, and it is not known whether
other members of the calpain family are inhibited by calpastatin. As we have discussed,
both µ- and m-calpain are likely present in axons, even though their relative amounts
may be debated. As µ- and m-calpains serve different, but critical physiologic roles,
selective targeting of the isoform or isoforms responsible for axonal injury may be
necessary to minimize adverse effects. In our laboratory, we have used RNA
interference to knock down m-calpain in primary hippocampal neurons, thereby
protecting them from excitotoxic injury (Bevers et al., 2009). We can use these same
tools in DRG cultures to answer the question of which isoform is responsible for the
degeneration of transected neurites. The most straightforward way to address this
question in vivo would be to use transgenic animals. There exists a µ-calpain knockout
mouse that is viable and fertile, and its major abnormalities involve platelet function
(Azam et al., 2001). Unfortunately, constitutive knockout of calpain 2 or the common
small regulatory subunit, which is required for stability and activity of µ - and m-calpain,
is embryonically lethal (Arthur et al., 2000; Dutt et al., 2006). Using conditional knockout
mice may overcome this obstacle.
Previous studies have clearly established that the majority of degenerating CNS
and PNS axons have different morphologies (Marques et al., 2003; Narciso et al., 2001).
In our study, although calpastatin overexpression provided robust biochemical protection
in both, it was unexpected that the morphological protection was much less apparent in
CNS than in PNS axons. Based on the biochemical data, transected axons in transgenic
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mice undergoing “dark” degeneration probably had preserved ultrastructure. The
molecular mechanism and functional significance of “dark” degeneration are unknown.
My dissertation has partly addressed the role of calpains in Wallerian
degeneration and TAI. Transection of mammalian CNS and PNS axons results in
irreversible degeneration of the distal segments. However, understanding the molecular
mechanism or mechanisms underlying axonal degeneration is potentially critical for
ameliorating many acute and chronic human diseases. In particular, there is a large
group of toxic and genetic disorders in which degeneration is most prominent in distal
parts of axons, known as “dying back” neuropathies (Coleman, 2005). In “dying back”
neuropathies, degeneration starts distally on axons and spreads retrogradely. Our
hCAST transgenic mouse is a powerful tool to address the role of calpains in these
disorders. For example, our mice could be crossed with progressive motor neuropathy
(pmn) mice or myelin protein zero (P0) null mutants – a model of Charcot-Marie-Tooth
disease.
Our hCAST transgenic mice could also be used more broadly, by addressing the
role of calpains in neurodegenerative disorders, for example. It has become clear that
most, and possibly all, neurodegenerative diseases involve major synapse and axon
loss prior to the appearance of symptoms, and long before neuronal loss is evident
(Saxena and Caroni, 2007). These diseases include Alzheimer’s, Parkinson’s,
Huntington’s, motor neuron disease, and prion diseases, and there is evidence that
calpains may play a role in their pathogenesis (Bizat et al., 2005; Crocker et al., 2003;
Kieran and Greensmith, 2004; Li et al., 1998; Trancikova et al., 2011; Trinchese et al.,
2008; Yadavalli et al., 2004). There are transgenic mouse models for many
neurodegenerative disorders (see review by Trancikova et al., 2011).
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Interaction of calpains with other axon degeneration pathways
It was once believed that transected axons, deprived of nutrients from the
somata, passively wasted away. However, with the identification and characterization of
the Wlds mutation, that is no longer considered true. Axon degeneration is an active,
tightly controlled process, and from that perspective, similar to apoptosis. However,
there is strong evidence that the apoptotic machinery is not important in Wallerian
degeneration (Finn et al., 2000; Kilinc et al., 2010; Schoenmann et al., 2010; Whitmore
et al., 2003). There are two other non-calpain mechanisms that may contribute to axonal
degeneration: the ubiquitin-proteasome system (UPS) and autophagy (Knöferle et al.,
2010; Zhai et al., 2003;). Much less is known about the role of autophagy in axonal
degeneration. To end this dissertation, I will briefly discuss UPS and a potential
convergence between calpains and the UPS.
The notion that UPS may be important in WD came from the identification of the
Wlds gene, which is formed by a stable triplication encoding the N-terminus of
multiubiquitylation factor Ube4b fused in-frame to the Nmnat1. In the UPS, ubiquitin is
conjugated to proteins to signal their degradation by the proteasome, an abundant ATPdependent protease. Inhibition of UPS, but not calpains, protects the axolemma and
microtubule structure of transected neurites (Zhai et al., 2003). Inhibiting either UPS or
calpains protects neurofilaments however. These results suggest that the UPS and
calpains may act on different aspects of Wallerian degeneration. Axonal protection with
UPS inhibition by pharmacologic and genetic means was confirmed in vivo (Hoopfer et
al., 2006; Wakatsuki et al., 2011; Zhai et al., 2003). Wakatsuki and colleagues (2011)
described an elegant pathway linking ZNRF1 ubiquitin ligase to axonal degeneration.
Through a series of intermediaries, activation of ZNRF1 results in the phosphorylation at
the 514th threonine residue of collapsing response mediator protein-2 (CRMP2),
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abolishing its stabilizing activity on microtubules. Interestingly, calpains are known to
cleave CRMP2 at its C-terminus (Touma et al., 2007; Zhang et al., 2007). Proteolysis is
not predicted to affect its binding to microtubules, but may alter tubulin transport. Even
though the cleavage site is not known, it is likely near to the 514th amino acid. The
interplay between proteolysis and phosphorylation of CRMP2 in Wallerian degeneration
may be worthy of study.

Final Conclusions
In summary, I show that calpains play a causal role in key aspects of axonal
dysfunction and degeneration in several different injury models. Additionally, the tools
and models employed or developed in the course of this research may have an impact
on elucidating molecular mechanisms underlying diverse human diseases. The hCAST
transgenic mouse is a powerful tool to study the role of calpains in a wide spectrum of
disorders. In addition, studying the interplay of calpains with other axon degeneration
pathways may yield important insights.
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